OA17911A - Quinazolin-THF-amines as PDE1 inhibitors. - Google Patents
Quinazolin-THF-amines as PDE1 inhibitors. Download PDFInfo
- Publication number
- OA17911A OA17911A OA1201600249 OA17911A OA 17911 A OA17911 A OA 17911A OA 1201600249 OA1201600249 OA 1201600249 OA 17911 A OA17911 A OA 17911A
- Authority
- OA
- OAPI
- Prior art keywords
- amine
- quinazolin
- dimethoxy
- tetrahydrofuran
- compound
- Prior art date
Links
- 101700084262 PDE1C Proteins 0.000 title abstract description 41
- 230000002401 inhibitory effect Effects 0.000 title abstract description 16
- 239000003112 inhibitor Substances 0.000 title abstract description 15
- 150000001875 compounds Chemical class 0.000 claims description 101
- 239000000203 mixture Substances 0.000 claims description 54
- -1 7,8-Dimethoxy-N-(tetrahydrofuran-3-yl)quinazolin-4-amine trans-N-(-2-cyclopropyltetrahydrofuran-3-yl)-7,8-dimethoxyquinazolin-4-amine Chemical compound 0.000 claims description 27
- DRYRBWIFRVMRPV-UHFFFAOYSA-N quinazolin-4-amine Chemical compound C1=CC=C2C(N)=NC=NC2=C1 DRYRBWIFRVMRPV-UHFFFAOYSA-N 0.000 claims description 23
- 229910052739 hydrogen Inorganic materials 0.000 claims description 18
- 239000011780 sodium chloride Substances 0.000 claims description 16
- 150000003839 salts Chemical class 0.000 claims description 15
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 14
- 201000000980 schizophrenia Diseases 0.000 claims description 14
- 238000007792 addition Methods 0.000 claims description 11
- 125000000217 alkyl group Chemical group 0.000 claims description 11
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 10
- 206010057668 Cognitive disease Diseases 0.000 claims description 9
- 239000002253 acid Substances 0.000 claims description 8
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 6
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 4
- 206010003736 Attention deficit/hyperactivity disease Diseases 0.000 claims description 4
- UNZQGYGNQRJGQE-NXEZZACHSA-N COC1=CC=C2C(=NC=NC2=C1OC)N[C@H]1[C@@H](COC1)O Chemical compound COC1=CC=C2C(=NC=NC2=C1OC)N[C@H]1[C@@H](COC1)O UNZQGYGNQRJGQE-NXEZZACHSA-N 0.000 claims description 4
- 230000000875 corresponding Effects 0.000 claims description 4
- XDPCNPCKDGQBAN-UHFFFAOYSA-N 3-Hydroxytetrahydrofuran Chemical compound OC1CCOC1 XDPCNPCKDGQBAN-UHFFFAOYSA-N 0.000 claims description 3
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 3
- 230000003287 optical Effects 0.000 claims description 3
- 125000003884 phenylalkyl group Chemical group 0.000 claims description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
- 125000004344 phenylpropyl group Chemical group 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 201000006287 attention deficit hyperactivity disease Diseases 0.000 claims 2
- 201000000368 schizophrenia 8 Diseases 0.000 claims 1
- 206010053643 Neurodegenerative disease Diseases 0.000 abstract description 12
- 239000003814 drug Substances 0.000 abstract description 12
- 206010037175 Psychiatric disease Diseases 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 102
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 54
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 50
- 239000000243 solution Substances 0.000 description 44
- 201000010099 disease Diseases 0.000 description 43
- 229940093499 ethyl acetate Drugs 0.000 description 34
- 235000019439 ethyl acetate Nutrition 0.000 description 34
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 28
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 28
- 239000012267 brine Substances 0.000 description 22
- 238000006243 chemical reaction Methods 0.000 description 20
- 239000007787 solid Substances 0.000 description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 19
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 18
- KFZMGEQAYNKOFK-UHFFFAOYSA-N iso-propanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 17
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 16
- 102100014454 PDE1A Human genes 0.000 description 15
- 238000003818 flash chromatography Methods 0.000 description 15
- RZPKBBLAXBUADI-UHFFFAOYSA-N 4-chloro-7,8-dimethoxyquinazoline Chemical compound ClC1=NC=NC2=C(OC)C(OC)=CC=C21 RZPKBBLAXBUADI-UHFFFAOYSA-N 0.000 description 14
- 101700006323 PDE1A Proteins 0.000 description 14
- 102100014455 PDE1B Human genes 0.000 description 14
- 101700071589 PDE1B Proteins 0.000 description 14
- BZKBCQXYZZXSCO-UHFFFAOYSA-N sodium hydride Inorganic materials [H-].[Na+] BZKBCQXYZZXSCO-UHFFFAOYSA-N 0.000 description 14
- 239000008194 pharmaceutical composition Substances 0.000 description 13
- 238000010828 elution Methods 0.000 description 12
- 108060002036 pde-2 Proteins 0.000 description 12
- UIIMBOGNXHQVGW-UHFFFAOYSA-M NaHCO3 Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 11
- IVOMOUWHDPKRLL-KQYNXXCUSA-N cAMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 11
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene dichloride Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 11
- 239000003208 petroleum Substances 0.000 description 11
- 239000002904 solvent Substances 0.000 description 11
- ZOOGRGPOEVQQDX-KHLHZJAASA-N Cyclic Guanosine Monophosphate Chemical compound C([C@H]1O2)O[P@](O)(=O)O[C@@H]1[C@H](O)[C@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-KHLHZJAASA-N 0.000 description 10
- 206010012289 Dementia Diseases 0.000 description 10
- 241000124008 Mammalia Species 0.000 description 10
- 239000007832 Na2SO4 Substances 0.000 description 10
- 102100014456 PDE1C Human genes 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Chemical group CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 10
- 239000003085 diluting agent Substances 0.000 description 10
- 229940079593 drugs Drugs 0.000 description 10
- 239000012074 organic phase Substances 0.000 description 10
- 239000000741 silica gel Substances 0.000 description 10
- 229910002027 silica gel Inorganic materials 0.000 description 10
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 10
- 229910052938 sodium sulfate Inorganic materials 0.000 description 10
- 238000005160 1H NMR spectroscopy Methods 0.000 description 8
- RSLOFNZXVCBZSF-UHFFFAOYSA-N CC1OCCC1(C)NC1=NC=NC2=C(C(=CC=C12)OC)OC Chemical compound CC1OCCC1(C)NC1=NC=NC2=C(C(=CC=C12)OC)OC RSLOFNZXVCBZSF-UHFFFAOYSA-N 0.000 description 8
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 8
- CSNNHWWHGAXBCP-UHFFFAOYSA-L magnesium sulphate Substances [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 8
- KZVGDSXTLLMZGO-VIFPVBQESA-N COC1=CC=C2C(=NC=NC2=C1OC)N[C@@H]1COCC1 Chemical compound COC1=CC=C2C(=NC=NC2=C1OC)N[C@@H]1COCC1 KZVGDSXTLLMZGO-VIFPVBQESA-N 0.000 description 7
- KZVGDSXTLLMZGO-SECBINFHSA-N COC1=CC=C2C(=NC=NC2=C1OC)N[C@H]1COCC1 Chemical compound COC1=CC=C2C(=NC=NC2=C1OC)N[C@H]1COCC1 KZVGDSXTLLMZGO-SECBINFHSA-N 0.000 description 7
- 239000003937 drug carrier Substances 0.000 description 7
- 230000004770 neurodegeneration Effects 0.000 description 7
- 210000002569 neurons Anatomy 0.000 description 7
- FMVYIDXJOGBYMO-UHFFFAOYSA-N COC1=CC=C2C(=NC=NC2=C1OC)NC1C(OCC1)C Chemical compound COC1=CC=C2C(=NC=NC2=C1OC)NC1C(OCC1)C FMVYIDXJOGBYMO-UHFFFAOYSA-N 0.000 description 6
- 201000001971 Huntington's disease Diseases 0.000 description 6
- PQLVXDKIJBQVDF-UHFFFAOYSA-N acetic acid;hydrate Chemical compound O.CC(O)=O PQLVXDKIJBQVDF-UHFFFAOYSA-N 0.000 description 6
- 239000000969 carrier Substances 0.000 description 6
- 239000012043 crude product Substances 0.000 description 6
- 125000004122 cyclic group Chemical group 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 239000003176 neuroleptic agent Substances 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- 230000001105 regulatory Effects 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- VXFZFGZMWIJVIB-UHFFFAOYSA-N COC1=CC=C2C(=NC=NC2=C1OC)N(C1COCC1)C Chemical compound COC1=CC=C2C(=NC=NC2=C1OC)N(C1COCC1)C VXFZFGZMWIJVIB-UHFFFAOYSA-N 0.000 description 5
- GKMJHXZVCMWMEE-UHFFFAOYSA-N COC1=CC=C2C(=NC=NC2=C1OC)NC1(COCC1)C Chemical compound COC1=CC=C2C(=NC=NC2=C1OC)NC1(COCC1)C GKMJHXZVCMWMEE-UHFFFAOYSA-N 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 206010061536 Parkinson's disease Diseases 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 238000002953 preparative HPLC Methods 0.000 description 5
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 5
- 230000001225 therapeutic Effects 0.000 description 5
- 206010001897 Alzheimer's disease Diseases 0.000 description 4
- RZWCBJXWNBLCCY-DOMZBBRYSA-N C1(CC1)[C@@H]1OCC[C@H]1NC1=NC=NC2=C(C(=CC=C12)OC)OC Chemical compound C1(CC1)[C@@H]1OCC[C@H]1NC1=NC=NC2=C(C(=CC=C12)OC)OC RZWCBJXWNBLCCY-DOMZBBRYSA-N 0.000 description 4
- MCFYNJGKGGKOOA-UHFFFAOYSA-N CC1(OCCC1NC1=NC=NC2=C(C(=CC=C12)OC)OC)C Chemical compound CC1(OCCC1NC1=NC=NC2=C(C(=CC=C12)OC)OC)C MCFYNJGKGGKOOA-UHFFFAOYSA-N 0.000 description 4
- VXOHBSUKENBHBI-UHFFFAOYSA-N COC1=CC=C2C(=NC=NC2=C1OC)N(C1C(OCC1)C)C Chemical compound COC1=CC=C2C(=NC=NC2=C1OC)N(C1C(OCC1)C)C VXOHBSUKENBHBI-UHFFFAOYSA-N 0.000 description 4
- VXFZFGZMWIJVIB-JTQLQIEISA-N COC1=CC=C2C(=NC=NC2=C1OC)N([C@@H]1COCC1)C Chemical compound COC1=CC=C2C(=NC=NC2=C1OC)N([C@@H]1COCC1)C VXFZFGZMWIJVIB-JTQLQIEISA-N 0.000 description 4
- 206010022114 Injury Diseases 0.000 description 4
- 206010034721 Personality disease Diseases 0.000 description 4
- 102000001708 Protein Isoforms Human genes 0.000 description 4
- 108010029485 Protein Isoforms Proteins 0.000 description 4
- 206010061920 Psychotic disease Diseases 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 230000000240 adjuvant Effects 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 125000004432 carbon atoms Chemical group C* 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 125000001072 heteroaryl group Chemical group 0.000 description 4
- 150000007522 mineralic acids Chemical class 0.000 description 4
- 230000036651 mood Effects 0.000 description 4
- 201000009457 movement disease Diseases 0.000 description 4
- IMNFDUFMRHMDMM-UHFFFAOYSA-N n-heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 4
- 230000001537 neural Effects 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 150000007524 organic acids Chemical class 0.000 description 4
- 239000012044 organic layer Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 206010065040 AIDS dementia complex Diseases 0.000 description 3
- HSNCKDOMOXGEGV-INIZCTEOSA-N C(C1=CC=CC=C1)N(C1=NC=NC2=C(C(=CC=C12)OC)OC)[C@@H]1COCC1 Chemical compound C(C1=CC=CC=C1)N(C1=NC=NC2=C(C(=CC=C12)OC)OC)[C@@H]1COCC1 HSNCKDOMOXGEGV-INIZCTEOSA-N 0.000 description 3
- HSNCKDOMOXGEGV-MRXNPFEDSA-N C(C1=CC=CC=C1)N(C1=NC=NC2=C(C(=CC=C12)OC)OC)[C@H]1COCC1 Chemical compound C(C1=CC=CC=C1)N(C1=NC=NC2=C(C(=CC=C12)OC)OC)[C@H]1COCC1 HSNCKDOMOXGEGV-MRXNPFEDSA-N 0.000 description 3
- PWXRXGBLFXKRER-ZDUSSCGKSA-N C1(CC1)CN(C1=NC=NC2=C(C(=CC=C12)OC)OC)[C@@H]1COCC1 Chemical compound C1(CC1)CN(C1=NC=NC2=C(C(=CC=C12)OC)OC)[C@@H]1COCC1 PWXRXGBLFXKRER-ZDUSSCGKSA-N 0.000 description 3
- PWXRXGBLFXKRER-CYBMUJFWSA-N C1(CC1)CN(C1=NC=NC2=C(C(=CC=C12)OC)OC)[C@H]1COCC1 Chemical compound C1(CC1)CN(C1=NC=NC2=C(C(=CC=C12)OC)OC)[C@H]1COCC1 PWXRXGBLFXKRER-CYBMUJFWSA-N 0.000 description 3
- CRVMJUFCDHZPOY-UHFFFAOYSA-N COC1=CC=C2C(=NC=NC2=C1OC)N(C1(COCC1)C)C Chemical compound COC1=CC=C2C(=NC=NC2=C1OC)N(C1(COCC1)C)C CRVMJUFCDHZPOY-UHFFFAOYSA-N 0.000 description 3
- 210000003169 Central Nervous System Anatomy 0.000 description 3
- 206010012256 Delusional disease Diseases 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 208000005314 Multi-Infarct Dementia Diseases 0.000 description 3
- IPOISSAYJDJXIK-UHFFFAOYSA-N N-(2,3-dimethyloxolan-3-yl)-7,8-dimethoxy-N-methylquinazolin-4-amine Chemical compound N=1C=NC2=C(OC)C(OC)=CC=C2C=1N(C)C1(C)CCOC1C IPOISSAYJDJXIK-UHFFFAOYSA-N 0.000 description 3
- 206010037211 Psychomotor hyperactivity Diseases 0.000 description 3
- 125000003545 alkoxy group Chemical group 0.000 description 3
- 239000000164 antipsychotic agent Substances 0.000 description 3
- 238000004166 bioassay Methods 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 210000004027 cells Anatomy 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000004064 dysfunction Effects 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- 230000002708 enhancing Effects 0.000 description 3
- 239000012458 free base Substances 0.000 description 3
- 125000005842 heteroatoms Chemical group 0.000 description 3
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000000051 modifying Effects 0.000 description 3
- 201000008895 mood disease Diseases 0.000 description 3
- 201000008839 post-traumatic stress disease Diseases 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000010898 silica gel chromatography Methods 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- COVZYZSDYWQREU-UHFFFAOYSA-N 1,4-Butanediol, dimethanesulfonate Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 2
- OFBKKJZMUHQYIN-UHFFFAOYSA-N 2,2-dimethyloxolan-3-amine Chemical compound CC1(C)OCCC1N OFBKKJZMUHQYIN-UHFFFAOYSA-N 0.000 description 2
- SBFGOECBUWGUNY-UHFFFAOYSA-N 2,2-dimethyloxolan-3-one Chemical compound CC1(C)OCCC1=O SBFGOECBUWGUNY-UHFFFAOYSA-N 0.000 description 2
- VSAPWIUQDZKEBG-UHFFFAOYSA-N 3-methyloxolan-3-amine Chemical compound CC1(N)CCOC1 VSAPWIUQDZKEBG-UHFFFAOYSA-N 0.000 description 2
- 206010001954 Amnestic disease Diseases 0.000 description 2
- AGEZXYOZHKGVCM-UHFFFAOYSA-N Benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 2
- JLKKDSBGAOTSFD-NSHDSACASA-N C(C)N(C1=NC=NC2=C(C(=CC=C12)OC)OC)[C@@H]1COCC1 Chemical compound C(C)N(C1=NC=NC2=C(C(=CC=C12)OC)OC)[C@@H]1COCC1 JLKKDSBGAOTSFD-NSHDSACASA-N 0.000 description 2
- JLKKDSBGAOTSFD-LLVKDONJSA-N C(C)N(C1=NC=NC2=C(C(=CC=C12)OC)OC)[C@H]1COCC1 Chemical compound C(C)N(C1=NC=NC2=C(C(=CC=C12)OC)OC)[C@H]1COCC1 JLKKDSBGAOTSFD-LLVKDONJSA-N 0.000 description 2
- BKYLHANNDLNEDQ-UHFFFAOYSA-N CC1(OCCC1=NS(=O)C(C)(C)C)C Chemical compound CC1(OCCC1=NS(=O)C(C)(C)C)C BKYLHANNDLNEDQ-UHFFFAOYSA-N 0.000 description 2
- QKAMNZXIJAJWCL-LBPRGKRZSA-N COC1=CC=C2C(=NC=NC2=C1OC)N([C@@H]1COCC1)CCC Chemical compound COC1=CC=C2C(=NC=NC2=C1OC)N([C@@H]1COCC1)CCC QKAMNZXIJAJWCL-LBPRGKRZSA-N 0.000 description 2
- VXFZFGZMWIJVIB-SNVBAGLBSA-N COC1=CC=C2C(=NC=NC2=C1OC)N([C@H]1COCC1)C Chemical compound COC1=CC=C2C(=NC=NC2=C1OC)N([C@H]1COCC1)C VXFZFGZMWIJVIB-SNVBAGLBSA-N 0.000 description 2
- KZVGDSXTLLMZGO-UHFFFAOYSA-N COC1=CC=C2C(=NC=NC2=C1OC)NC1COCC1 Chemical compound COC1=CC=C2C(=NC=NC2=C1OC)NC1COCC1 KZVGDSXTLLMZGO-UHFFFAOYSA-N 0.000 description 2
- 102000000584 Calmodulin Human genes 0.000 description 2
- 108010041952 Calmodulin Proteins 0.000 description 2
- 241000218236 Cannabis Species 0.000 description 2
- 210000003917 Chromosomes, Human Anatomy 0.000 description 2
- 206010012218 Delirium Diseases 0.000 description 2
- 206010013663 Drug dependence Diseases 0.000 description 2
- 206010049669 Dyscalculia Diseases 0.000 description 2
- 206010058319 Dysgraphia Diseases 0.000 description 2
- 206010013932 Dyslexia Diseases 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- LNEPOXFFQSENCJ-UHFFFAOYSA-N Haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 2
- 206010024094 Learning disease Diseases 0.000 description 2
- BZLVMXJERCGZMT-UHFFFAOYSA-N MeOtBu Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
- 206010027378 Mental retardation Diseases 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N Methyl iodide Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 229940005483 OPIOID ANALGESICS Drugs 0.000 description 2
- KVWDHTXUZHCGIO-UHFFFAOYSA-N Olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 description 2
- DZOJBGLFWINFBF-UMSFTDKQSA-N Osanetant Chemical compound C([C@](C1)(CCCN2CCC(CC2)(N(C(C)=O)C)C=2C=CC=CC=2)C=2C=C(Cl)C(Cl)=CC=2)CCN1C(=O)C1=CC=CC=C1 DZOJBGLFWINFBF-UMSFTDKQSA-N 0.000 description 2
- 229950009875 Osanetant Drugs 0.000 description 2
- 235000019483 Peanut oil Nutrition 0.000 description 2
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N Phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 2
- URKOMYMAXPYINW-UHFFFAOYSA-N Quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 description 2
- 206010037999 Reading disease Diseases 0.000 description 2
- 208000005793 Restless Legs Syndrome Diseases 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N Salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- GZKLJWGUPQBVJQ-UHFFFAOYSA-N Sertindole Chemical compound C1=CC(F)=CC=C1N1C2=CC=C(Cl)C=C2C(C2CCN(CCN3C(NCC3)=O)CC2)=C1 GZKLJWGUPQBVJQ-UHFFFAOYSA-N 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N Stearic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 206010072388 Substance-induced psychotic disease Diseases 0.000 description 2
- 231100000393 Substance-induced psychotic disorder Toxicity 0.000 description 2
- MVWVFYHBGMAFLY-UHFFFAOYSA-N Ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 description 2
- RQBBFKINEJYDOB-UHFFFAOYSA-N acetic acid;acetonitrile Chemical group CC#N.CC(O)=O RQBBFKINEJYDOB-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000001476 alcoholic Effects 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 239000003693 atypical antipsychotic agent Substances 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- AEILLAXRDHDKDY-UHFFFAOYSA-N bromomethylcyclopropane Chemical compound BrCC1CC1 AEILLAXRDHDKDY-UHFFFAOYSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000003197 catalytic Effects 0.000 description 2
- 230000019771 cognition Effects 0.000 description 2
- 230000001149 cognitive Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000001054 cortical Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000002532 enzyme inhibitor Substances 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000000380 hallucinogen Substances 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 229960003878 haloperidol Drugs 0.000 description 2
- 201000006347 intellectual disability Diseases 0.000 description 2
- 230000003834 intracellular Effects 0.000 description 2
- 238000007917 intracranial administration Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000007913 intrathecal administration Methods 0.000 description 2
- 125000000842 isoxazolyl group Chemical group 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 201000003723 learning disability Diseases 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- 230000000926 neurological Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 229960005017 olanzapine Drugs 0.000 description 2
- 230000003364 opioid Effects 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000000312 peanut oil Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 229950010883 phencyclidine Drugs 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 230000000865 phosphorylative Effects 0.000 description 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 2
- 229960004431 quetiapine Drugs 0.000 description 2
- 201000000978 schizoaffective disease Diseases 0.000 description 2
- 201000000261 schizophreniform disease Diseases 0.000 description 2
- 229960000652 sertindole Drugs 0.000 description 2
- YOQDYZUWIQVZSF-UHFFFAOYSA-N sodium borohydride Chemical compound [BH4-].[Na+] YOQDYZUWIQVZSF-UHFFFAOYSA-N 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 230000002459 sustained Effects 0.000 description 2
- 230000005062 synaptic transmission Effects 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 2
- 238000001946 ultra-performance liquid chromatography-mass spectrometry Methods 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- 229960000607 ziprasidone Drugs 0.000 description 2
- MHOVLDXJDIEEMJ-PGMHMLKASA-N (3R)-oxolan-3-amine;hydrochloride Chemical compound Cl.N[C@@H]1CCOC1 MHOVLDXJDIEEMJ-PGMHMLKASA-N 0.000 description 1
- MHOVLDXJDIEEMJ-WCCKRBBISA-N (3S)-oxolan-3-amine;hydrochloride Chemical compound Cl.N[C@H]1CCOC1 MHOVLDXJDIEEMJ-WCCKRBBISA-N 0.000 description 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- AUEKAKHRRYWONI-UHFFFAOYSA-N 1-(4,4-diphenylbutyl)piperidine Chemical class C1CCCCN1CCCC(C=1C=CC=CC=1)C1=CC=CC=C1 AUEKAKHRRYWONI-UHFFFAOYSA-N 0.000 description 1
- LKKUYGGQEIJGDR-UHFFFAOYSA-N 1-iodopropane Chemical compound [CH2]CCI LKKUYGGQEIJGDR-UHFFFAOYSA-N 0.000 description 1
- AXWLTIYDQWQSEC-UHFFFAOYSA-N 2,3-dimethyloxolan-3-amine Chemical compound CC1OCCC1(C)N AXWLTIYDQWQSEC-UHFFFAOYSA-N 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- CESUXLKAADQNTB-SSDOTTSWSA-N 2-methylpropane-2-sulfinamide Chemical compound CC(C)(C)[S@](N)=O CESUXLKAADQNTB-SSDOTTSWSA-N 0.000 description 1
- XFDDJSOAVIFVIH-UHFFFAOYSA-N 4-aminooxolan-3-ol;hydrochloride Chemical compound Cl.NC1COCC1O XFDDJSOAVIFVIH-UHFFFAOYSA-N 0.000 description 1
- RJBDIZOPMJXBIC-UHFFFAOYSA-N 7,8-dimethoxyquinazoline Chemical compound C1=NC=NC2=C(OC)C(OC)=CC=C21 RJBDIZOPMJXBIC-UHFFFAOYSA-N 0.000 description 1
- SKTFQHRVFFOHTQ-UHFFFAOYSA-N 8-bromo-1,3-dimethyl-7H-purine-2,6-dione Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC(Br)=N2 SKTFQHRVFFOHTQ-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Natural products CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 208000008811 Agoraphobia Diseases 0.000 description 1
- 206010057666 Anxiety disease Diseases 0.000 description 1
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 description 1
- 206010004939 Bipolar I disease Diseases 0.000 description 1
- 206010004940 Bipolar II disease Diseases 0.000 description 1
- 206010004938 Bipolar disease Diseases 0.000 description 1
- 210000004556 Brain Anatomy 0.000 description 1
- FFSAXUULYPJSKH-UHFFFAOYSA-N Butyrophenone Chemical class CCCC(=O)C1=CC=CC=C1 FFSAXUULYPJSKH-UHFFFAOYSA-N 0.000 description 1
- IJNIVGLVDMZFHZ-RQJHMYQMSA-N C1(CC1)[C@@H]1OCC[C@H]1N Chemical compound C1(CC1)[C@@H]1OCC[C@H]1N IJNIVGLVDMZFHZ-RQJHMYQMSA-N 0.000 description 1
- ZXBPVQWHAQRHQN-UHFFFAOYSA-N CC1(OCCC1NS(=O)C(C)(C)C)C Chemical compound CC1(OCCC1NS(=O)C(C)(C)C)C ZXBPVQWHAQRHQN-UHFFFAOYSA-N 0.000 description 1
- QKAMNZXIJAJWCL-GFCCVEGCSA-N COC1=CC=C2C(=NC=NC2=C1OC)N([C@H]1COCC1)CCC Chemical compound COC1=CC=C2C(=NC=NC2=C1OC)N([C@H]1COCC1)CCC QKAMNZXIJAJWCL-GFCCVEGCSA-N 0.000 description 1
- WSFYFEIJLIHAFA-ZYHUDNBSSA-N COC1=CC=C2C(=NC=NC2=C1OC)N[C@@H]1COC[C@H]1OC Chemical compound COC1=CC=C2C(=NC=NC2=C1OC)N[C@@H]1COC[C@H]1OC WSFYFEIJLIHAFA-ZYHUDNBSSA-N 0.000 description 1
- 102000005701 Calcium-Binding Proteins Human genes 0.000 description 1
- 108010045403 Calcium-Binding Proteins Proteins 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 108091005504 Cation channels Proteins 0.000 description 1
- QZUDBNBUXVUHMW-UHFFFAOYSA-N Clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 102000004654 Cyclic GMP-Dependent Protein Kinases Human genes 0.000 description 1
- 108010003591 Cyclic GMP-Dependent Protein Kinases Proteins 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 206010012239 Delusion Diseases 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 208000001187 Dyskinesias Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 206010013982 Dysthymic disease Diseases 0.000 description 1
- 206010015037 Epilepsy Diseases 0.000 description 1
- HVTICUPFWKNHNG-UHFFFAOYSA-N Ethyl iodide Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
- HQDFCBGYMVHDNB-UHFFFAOYSA-N FC(C(=O)O)(F)F.CC1OCCC1N Chemical compound FC(C(=O)O)(F)F.CC1OCCC1N HQDFCBGYMVHDNB-UHFFFAOYSA-N 0.000 description 1
- 206010057671 Female sexual dysfunction Diseases 0.000 description 1
- 206010018075 Generalised anxiety disease Diseases 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-N Gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 1
- 229940074045 Glyceryl Distearate Drugs 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N HEPES Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 101700083699 HIS6 Proteins 0.000 description 1
- 208000004547 Hallucinations Diseases 0.000 description 1
- 210000001320 Hippocampus Anatomy 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 206010020993 Hypoglycaemia Diseases 0.000 description 1
- 206010021030 Hypomania Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- XJGVXQDUIWGIRW-UHFFFAOYSA-N Loxapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2OC2=CC=C(Cl)C=C12 XJGVXQDUIWGIRW-UHFFFAOYSA-N 0.000 description 1
- 206010026749 Mania Diseases 0.000 description 1
- KLPWJLBORRMFGK-UHFFFAOYSA-N Molindone Chemical compound O=C1C=2C(CC)=C(C)NC=2CCC1CN1CCOCC1 KLPWJLBORRMFGK-UHFFFAOYSA-N 0.000 description 1
- 208000001089 Multiple System Atrophy Diseases 0.000 description 1
- LQVZUXUQGFIYEK-UHFFFAOYSA-N N-methyloxolan-3-amine Chemical compound CNC1CCOC1 LQVZUXUQGFIYEK-UHFFFAOYSA-N 0.000 description 1
- 229910017906 NH3H2O Inorganic materials 0.000 description 1
- 210000001577 Neostriatum Anatomy 0.000 description 1
- 102000007072 Nerve Growth Factors Human genes 0.000 description 1
- 108010008267 Nerve Growth Factors Proteins 0.000 description 1
- 208000009025 Nervous System Disease Diseases 0.000 description 1
- 206010029305 Neurological disorder Diseases 0.000 description 1
- 231100000618 Neurotoxin Toxicity 0.000 description 1
- 102000022497 PDE1 family Human genes 0.000 description 1
- 108091011010 PDE1 family Proteins 0.000 description 1
- 102100018801 PDE5A Human genes 0.000 description 1
- 101700034664 PDE5A Proteins 0.000 description 1
- 206010033666 Panic disease Diseases 0.000 description 1
- 108060002038 Pde4 Proteins 0.000 description 1
- 206010034912 Phobia Diseases 0.000 description 1
- 229940067631 Phospholipids Drugs 0.000 description 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N Picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- YVUQSNJEYSNKRX-UHFFFAOYSA-N Pimozide Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)CCCN1CCC(N2C(NC3=CC=CC=C32)=O)CC1 YVUQSNJEYSNKRX-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 102000001253 Protein Kinases Human genes 0.000 description 1
- 108060006633 Protein Kinases Proteins 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010041250 Social phobia Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000004490 Stress Disorders, Traumatic, Acute Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 1
- 108020003835 TX1 Proteins 0.000 description 1
- 229960000278 Theophylline Drugs 0.000 description 1
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N Theophylline Natural products O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 1
- 206010043835 Tic disease Diseases 0.000 description 1
- 230000036335 Tissue distribution Effects 0.000 description 1
- 208000000323 Tourette Syndrome Diseases 0.000 description 1
- 206010044126 Tourette's disease Diseases 0.000 description 1
- 229940046009 Vitamin E Drugs 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- WFPIAZLQTJBIFN-DVZOWYKESA-N Zuclopenthixol Chemical compound C1CN(CCO)CCN1CC\C=C\1C2=CC(Cl)=CC=C2SC2=CC=CC=C2/1 WFPIAZLQTJBIFN-DVZOWYKESA-N 0.000 description 1
- 229960004141 Zuclopenthixol Drugs 0.000 description 1
- BIDHTLIFGLSEPA-UHFFFAOYSA-N [Cl-].CC1OCCC1[NH3+] Chemical compound [Cl-].CC1OCCC1[NH3+] BIDHTLIFGLSEPA-UHFFFAOYSA-N 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- UGAPHEBNTGUMBB-UHFFFAOYSA-N acetic acid;ethyl acetate Chemical compound CC(O)=O.CCOC(C)=O UGAPHEBNTGUMBB-UHFFFAOYSA-N 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000001154 acute Effects 0.000 description 1
- 201000005913 acute stress disease Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229960004372 aripiprazole Drugs 0.000 description 1
- 238000000065 atmospheric pressure chemical ionisation Methods 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 150000008316 benzisoxazoles Chemical class 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 230000037348 biosynthesis Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- OSGAYBCDTDRGGQ-UHFFFAOYSA-N calcium;sulfuric acid Chemical compound [Ca+2].OS(O)(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-N 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 229960004170 clozapine Drugs 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 230000000593 degrading Effects 0.000 description 1
- 231100000868 delusion Toxicity 0.000 description 1
- 230000001419 dependent Effects 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- PHGLEWRBYHCKII-AXFPHJBVSA-N dioxido(oxo)silane;yttrium-90(3+) Chemical compound [90Y+3].[90Y+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O.[O-][Si]([O-])=O PHGLEWRBYHCKII-AXFPHJBVSA-N 0.000 description 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- KVXNKFYSHAUJIA-UHFFFAOYSA-M ethoxyethane;acetate Chemical compound CC([O-])=O.CCOCC KVXNKFYSHAUJIA-UHFFFAOYSA-M 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 201000006529 generalized anxiety disease Diseases 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- MVFGXYPEQHIKIX-UHFFFAOYSA-M heptane;acetate Chemical compound CC([O-])=O.CCCCCCC MVFGXYPEQHIKIX-UHFFFAOYSA-M 0.000 description 1
- 101710008935 hisHF Proteins 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002218 hypoglycaemic Effects 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 229960000423 loxapine Drugs 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- XYVQFUJDGOBPQI-UHFFFAOYSA-N methyl 2-hydroxy-2-methylpropanoate Chemical compound COC(=O)C(C)(C)O XYVQFUJDGOBPQI-UHFFFAOYSA-N 0.000 description 1
- QBIYSJGOWOLLIO-UHFFFAOYSA-N methyl 5,5-dimethyl-4-oxooxolane-3-carboxylate Chemical compound COC(=O)C1COC(C)(C)C1=O QBIYSJGOWOLLIO-UHFFFAOYSA-N 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000006011 modification reaction Methods 0.000 description 1
- 229960004938 molindone Drugs 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 150000004712 monophosphates Chemical class 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 201000003631 narcolepsy Diseases 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000000626 neurodegenerative Effects 0.000 description 1
- 230000005015 neuronal process Effects 0.000 description 1
- 230000000324 neuroprotective Effects 0.000 description 1
- 239000002581 neurotoxin Substances 0.000 description 1
- 239000003900 neurotrophic factor Substances 0.000 description 1
- 230000000508 neurotrotrophic Effects 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N nitric acid Chemical class O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 201000008430 obsessive-compulsive disease Diseases 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- MIPHRQMEIYLZFZ-UHFFFAOYSA-N oxolan-3-amine Chemical compound NC1CCOC1 MIPHRQMEIYLZFZ-UHFFFAOYSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N p-acetaminophenol Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 125000005489 p-toluenesulfonic acid group Chemical class 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- 229960003357 pamabrom Drugs 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 108060002037 pde-3 Proteins 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 150000002990 phenothiazines Chemical class 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 201000001552 phobic disease Diseases 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229960003634 pimozide Drugs 0.000 description 1
- 150000004885 piperazines Chemical class 0.000 description 1
- 150000003053 piperidines Chemical class 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning Effects 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002335 preservative Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged Effects 0.000 description 1
- 230000002685 pulmonary Effects 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N rac-1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- 108700000006 regulatory domains Proteins 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 231100000486 side effect Toxicity 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000004083 survival Effects 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 150000005075 thioxanthenes Chemical class 0.000 description 1
- 230000000699 topical Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 150000003712 vitamin E derivatives Chemical class 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
Abstract
The present invention provides QuinazolinTHF-amines
as PDE1 inhibitors and their use as a
medicament, in particular for the treatment of
neurodegenerative disorders and psychiatric
disorders.
Description
FIELD OF THE INVENTION
The présent invention provides compounds that are PDE1 enzyme inhibitors and their use as a médicament, in particular for the treatment of neurodegenerative disorders and psychiatrie disorders. The présent invention also provides pharmaceutical compositions comprising compounds of the invention and methods of treating disorders using the compounds of the invention.
BACKGROUND OF THE INVENTION
Throughout this application, various publications are referenced in full. The disclosures of these publications are hereby incorporated by référencé into this application to describe more fully the state of the art to which this invention pertains.
The second messenger cyclic Nucléotides (cNs), cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) play a major rôle in intracellular signal transduction cascade, by regulating cN-dependent protein kinases (PKA and PKG), EPACs (Exchange Protein Activated by cAMP), phosphoprotein phosphatases, and/or cN-gated cation channels. In neurons, this includes the activation of cAMP- and cGMP-dependent kinases and subséquent phosphorylation of proteins involved in acute régulation of synaptic transmission as well as in neuronal différentiation and survival. Intracellular concentrations of cAMP and cGMP are strictly regulated by the rate of biosynthesis by cyclases and by the rate of dégradation by phosphodiesterases (PDEs, EC 3.1.4.17). PDEs are bimetallic hydrolases that inactivate cAMP/cGMP by catalytic hydrolysis of the 3’-ester bond, forming the inactive 5’monophosphate. Since PDEs provide the only means of degrading the cyclic nucléotides cAMP and cGMP in cells, PDEs play an essential rôle in cyclic nucléotide signalling. The catalytic activities of PDEs provide for breakdown of cNs over a spectrum of concentrations in ail cells, and their varied regulatory mechanisms provide for intégration and crosstalk with myriad signalling pathways. Particular PDEs are targeted to discrète compartiments within cells where they control cN level and sculpt microenvironments for a variety of cN signalosomes (Sharron H. Francis, Mitsi A. Blount, and Jackie D. Corbin. Physiol Rev 2011, 91: 651-690).
On the basis of substrate specificity, the PDE families can be divided into three groups: 1) The cAMP-specific PDEs, which include PDE4, PDE7, and PDE8, 2) the cGMP-selective enzymes PDE5 and PDE9, and 3) the dual-substrate PDEs, PDE1, PDE2, PDE3, as well as PDE10 and PDE11.
Previously named calmodulin-stimulated PDE (CaM-PDE), PDE1 is unique in that it is Ca2+dependently regulated via calmodulin (CaM, a 16 kDa Ca2+-binding protein) complexed with four Ca2+ (for review, Sharron H. Francis, Mitsi A. Blount, and Jackie D. Corbin. Physiol Rev 2011, 91: 651-690). Thus, this family represents an interesting regulatory link between cyclic nucléotides and intracellular Ca2+. The PDE1 family is encoded by three genes: PDE1A (mapped on human chromosome 2q32), PDE1B (human chromosome location, hcl: 12q13) and PDE1C (hcl: 7p14.3). They hâve alternative promoters and give rise to a multitude of proteins by alternative splicing which differ in their regulatory properties, substrate affinities, spécifie activities, activation constants for CaM, tissue distribution and molecular weights. More than 10 human isoforms are identified. Their molecular weights vary from 58 to 86 kDa per monomer. The N-terminal regulatory domain that contains two Ca2+/CaM binding domains and two phosphorylation sites differentiate their corresponding proteins and modulate their biochemical functions. PDE1 is a dual substrate PDE and the PDE1 C-subtype has equal activity towards cAMP and cGMP (Km « 1-3 μΜ), whereas the subtypes PDE1A and PDE1B has a preference for cGMP (Km for cGMP « 1-3 μΜ and for cAMP ~ 10-30 pM).
The PDE1 subtypes are highly enriched in the brain and located especially in the striatum (PDE1B), hippocampus (PDE1A) and cortex (PDE1A) and this localization is conserved across species (Amy Bernard et al. Neuron 2012, 73, 1083-1099). In the cortex, PDE1A is présent mainly in deep cortical layers 5 and 6 (output layers), and used as a specificity marker for the deep cortical layers. PDE1 inhibitors enhance the levels of the second messenger cNs leading to enhanced neuronal excitability.
Thus, PDE1 is a therapeutic target for régulation of intracellular signalling pathways, preferably in the nervous System and PDE1 inhibitors can enhance the levels of the second messengers cAMP/cGMP leading to modulation of neuronal processes and to the expression of neuronal plasticity-related genes, neurotrophic factors, and neuroprotective molécules. These neuronal plasticity enhancement properties together with the modulation of synaptic transmission make PDE1 inhibitors good candidates as therapeutic agents in many neurological and psychiatrie conditions. The évaluation of PDE1 inhibitors in animal models (for reviews see e.g. Blokland et al. Expert Opinion on Therapeutic Patents (2012), 22(4), 349-354; and Médina, A. E. Frontiers in Neuropharmacology (2011), 5(Feb.), 21) hâve suggested the potential for the therapeutic use of PDE1 inhibitors in neurological disorders, like e.g. Alzheimer's, Parkinson's and Huntington's Diseases and in psychiatrie disorders like e.g. Attention Déficit hyperactivity Disorder (ADHD), restless leg syndrome, dépréssion, narcolepsy, cognitive impairment and cognitive impairment associated with schizophrenia (CIAS). There hâve also been patent applications claiming that
PDE1 inhibitors are useful in diseases that may be alleviated by the enhancement of progesterone-signalling such as female sexual dysfunction.
The compounds of the invention may offer alternatives to current marketed treatments for neurodegenerative and/or psychiatrie disorders, which are not efficacious in ail patients. Hence, there remains a need for alternative methods of treatment.
SUMMARY OF THE INVENTION
PDE1 enzymes are expressed in the Central Nervous System (CNS), making this gene family an attractive source of new targets for the treatment of psychiatrie and neurodegenerative disorders.
The objective of the présent invention is to provide compounds that are PDE1 inhibitors, and as such are useful to treat neurodegenerative disorders and psychiatrie disorders. In a preferred embodiment the compounds are sélective PDE1 inhibitors.
Accordingly, the présent invention relates to compounds of formula (I)
(I) wherein
R-i is selected from the group consisting of H and Cf to C3 alkyl;
R2 is selected from the group consisting of H and C1-C3 alkyl, wherein the CfC3 alkyl optionally is substituted one or more times with one or more substituents selected from the group consisting of phenyl and C3-C6 cycloalkyl,
R3 is selected from the group consisting of H, methyl and ethyl,
R4 is selected from the group consisting of H, hydroxy, methoxy and ethoxy,
R5, R6 and R7 are H,
R8 is selected from the group consisting of H, methyl, ethyl and cyclopropyl
Rg is selected from the group consisting of H, methyl and ethyl and pharmaceutically acceptable acid addition salts of Compound I, racemic mixtures of Compound I, or the corresponding enantiomer and/or optical isomer of Compound I, and polymorphie forms of Compound I as well as tautomeric forms of Compound I.
DETAILED DESCRIPTION OF THE INVENTION
EMBODIMENTS OF THE INVENTION
In a first embodiment (E1) the présent invention relates to compounds of formula (I) (Compound I)
Compound (I) wherein Ri is selected from the group consisting of H and CrC3 alkyl;
R2 is selected from the group consisting of H and CrC3 alkyl wherein the CrC3 alkyl optionally is substituted with phenyl or C3-C6 cycloalkyl;
R3 is selected from the group consisting of H, methyl and ethyl
R4 is selected from the group consisting of H, hydroxyl, methoxy and ethoxy and;
R5, R6 and R7 are H
R8 is selected from the group consisting of H, methyl, ethyl and cyclopropyl
Rg is selected from the group consisting of H, methyl and ethyl and pharmaceutically acceptable acid addition salts of Compound I, racemic mixtures of Compound I, or the corresponding enantiomer and/or optical isomer of Compound I, and polymorphie forms of Compound I as well as tautomeric forms of Compound I.In an embodiment (E2) of (E1 ) R2 is H.
In an embodiment (E3) of (E1 ) R2 is CH3.
In an embodiment (E4) of (E3) R2 is substituted with phenyl or cyclopropyl.
In an embodiment (E5) of (E1) Rt is methyl.
In an embodiment (E6) of any of any of (E1 ) to (E5) the compound is a PDE1 inhibitor.
In an embodiment (E7) of any of (E1 ) to (E6) the compound is seiected from the compounds of Table 1
In an embodiment (E8) of any of (E1 ) to (E7) the compound is for use as a médicament.
In an embodiment (E9) of any of (E1 ) to (E7) the compound is for use in treating ADHD, schizophrenia or cognitive impairment associated with schizophrenia.
Embodiment (E10) is the use of the compound of any of (E1 ) to (E7) for the manufacture of a médicament for the treatment of ADHD schizophrenia or cognitive impairment associated with schizophrenia.
DEFINITIONS
PDE1 ENZYMES
The PDE1 isozyme family includes numerous splice variant PDE1 isoforms. It has three subtypes, PDE1A, PDE1B and PDE1C which divide further into various isoforms. In the context of the présent invention PDE1 and PDE1 enzymes are synonymous and refer to PDE1A, PDE1B and PDE1C enzymes as well as their isoforms.
SUBSTITUENTS
As used in the context of the présent invention, the terms “halo” and “halogen” are used interchangeably and refer to fluorine, chlorine, bromine or iodine.
The terms ”CrC3 alkyl”, ”CrC4 alkyl”, C^Cs alkyl” and ”C-,-C6 alkyl” refer to a straight-chain or branched saturated hydrocarbon having from one to six carbon atoms, inclusive. Examples of such groups include, but are not limited to, methyl, ethyl, 1-propyl, 2-propyl, 1-butyl, 2-butyl, 2methyl-2-propyl, 2-methyl-1-butyl, and n-hexyl.
The term “C3-C6 cycloalkyl” typically refers to cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
The expression “alkoxy” refers to a straight-chain or branched saturated alkoxy group having from one to six carbon atoms, inclusive, with the open valency on the oxygen. Examples of such groups include, but are not limited to, methoxy, ethoxy, n-butoxy, 2-methyl-pentoxy and nhexyloxy.
The term “aryl” refers to a phenyl ring, optionally substituted with halogen, C-|-C6 alkyl, alkoxy or halo(C1-C6)alkyl as defined above.
The term “heteroaryl” monocyclic- or polycyclic aromatic ring comprising carbon atoms, hydrogen atoms, and one or more heteroatoms, preferably, 1 to 3 heteroatoms, independently selected from nitrogen, oxygen, and sulfur. Illustrative examples of heteroaryl groups include, but are not limited to, pyridinyl, pyridazinyl, triazinyl, pyrrolyl, pyrazolyl, imidazolyl, (1,2,3,)triazolyl, (1,2,4)-triazolyl, pyrazinyl, pyrimidinyl, tetrazolyl, furanyl, thiophenyl, isoxazolyl, thiazolyl, isoxazolyl, and oxazolyl.
A heteroaryl group can be unsubstituted or substituted with one or two suitable substituents. Preferably, the heteroaryl of this invention is a monocyclic 5 or 6 membered heteroaryl, wherein the ring comprises 2 to 5 carbon atoms and 1 to 3 heteroatoms, referred to herein as “monocyclic 5 or 6 membered heteroaryl”
ISOMERIC FORMS
Where compounds ofthe présent invention contain one or more chiral centers reference to any ofthe compounds will, unless otherwise specified, coverthe enantiomerically or diastereomerically pure compound as well as mixtures ofthe enantiomers or diastereomers in any ratio.
For example reference to the compound 7,8-dimethoxy-N-methyl-N-(tetrahydrofuran-3yl)quinazolin-4-amine without any further spécification covers (R)-7,8-dimethoxy-N-methyl-N(tetrahydrofuran-3-yl)quinazolin-4-amine, (S)-7,8-dimethoxy-N-methyl-N-(tetrahydrofuran-3yl)quinazolin-4-amine as well as mixtures ofthe enantiomers in any ratio, including the racemic mixture (±)7,8-dimethoxy-N-methyl-N-(tetrahydrofuran-3-yl)quinazolin-4-amine.
Correspondingly, reference to the compound 7,8-dimethoxy-N-(-2-methyltetrahydrofuran-3yl)quinazolin-4-amine without any further spécification covers ail four covers ail four stereoisomeric variants as well as mixtures thereof in any ratio, including the racemic mixture.
The above also applies where compounds of the invention contain more than two chiral centers.
PDE1 INHIBITORS
In the context of the présent invention a compound is considered to be a PDE1 inhibitor if the amount required to reach the IC50 level of PDE1B is 5 micro molar or less, preferably less than 4 micro molar, such as 3 micro molar or less, more preferably 2 micro molar or less, such as 1 micro molar or less, in particular 500 nM or less. In preferred embodiments the required amount of PDE1 inhibitor required to to reach the IC50 level of PDE1B is 400nM or less, such as 300 nM or less, 200nM or less, 100 nM or less, or even 80 nM or less, such as 50 nM or less, for example 25 nM or less.
PHARMACEUTICALLY ACCEPTABLE SALTS
The présent invention also comprises salts of the compounds, typically, pharmaceutically acceptable salts. Such salts include pharmaceutically acceptable acid addition salts. Acid addition salts include salts of inorganic acids as well as organic acids.
Représentative examples of suitable inorganic acids include hydrochloric, hydrobromic, hydroiodic, phosphoric, sulfuric, sulfamic, nitric acids and the like. Représentative examples of suitable organic acids include formic, acetic, trichloroacetic, trifluoroacetic, propionic, benzoic, cinnamic, citric, fumaric, glycolic, itaconic, lactic, methanesulfonic, maleic, malic, malonic, mandelic, oxalic, picric, pyruvic, salicylic, succinic, methane sulfonic, ethanesulfonic, tartaric, ascorbic, pamoic, bismethylene salicylic, ethanedisulfonic, gluconic, citraconic, aspartic, stearic, palmitic, EDTA, glycolic, p-aminobenzoic, glutamic, benzenesulfonic, p-toluenesulfonic acids, theophylline acetic acids, as well as the 8-halotheophyllines, for example 8-bromotheophylline and the like. Further examples of pharmaceutically acceptable inorganic or organic acid addition salts include the pharmaceutically acceptable salts listed in Berge, S.M. et al., J. Pharm. Sci. 1977, 66, 2, the contents of which are hereby incorporated by reference.
Furthermore, the compounds of this invention may exist in unsolvated as well as in solvated forms with pharmaceutically acceptable solvents such as water, éthanol and the like. In general, the solvated forms are considered équivalent to the unsolvated forms for the purposes of this invention.
THERAPEUTICALLY EFFECTIVE AMOUNT
In the présent context, the term therapeutically effective amount of a compound means an amount sufficient to cure, alleviate or partially arrest the clinical manifestations of a given disease and its complications in a therapeutic intervention comprising the administration of said compound. An amount adéquate to accomplish this is defined as therapeutically effective amount. Effective amounts for each purpose will dépend on the severity ofthe disease or injury as well as the weight and general state ofthe subject. Itwill be understood that determining an appropriate dosage may be achieved using routine expérimentation, by constructing a matrix of values and testing different points in the matrix, which is ail within the ordinary skills of a trained physician.
In the présent context, the term treatment and treating means the management and care of a patient for the purpose of combating a condition, such as a disease or a disorder. The term is intended to include the full spectrum of treatments for a given condition from which the patient is suffering, such as administration ofthe active compound to alleviate the symptoms or complications, to delay the progression ofthe disease, disorder or condition, to alleviate or relief the symptoms and complications, and/or to cure or eliminate the disease, disorder or condition as well as to prevent the condition, wherein prévention is to be understood as the management and care of a patient for the purpose of combating the disease, condition, or disorder and includes the administration of the active compounds to prevent the onset of the symptoms or complications. Nonetheless, prophylactic (préventive) and therapeutic (curative) treatments are two separate aspects ofthe invention. The patientto be treated is preferably a mammal, in particular a human being.
PHARMACEUTICAL COMPOSITIONS
The présent invention further provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I) and a pharmaceutically acceptable carrier or diluent. The présent invention also provides a pharmaceutical composition comprising a therapeutically effective amount of one of the spécifie compounds disclosed in the Experimental Section herein and a pharmaceutically acceptable carrier or diluent.
The compounds of the invention may be administered alone or in combination with pharmaceutically acceptable carriers, diluents or excipients, in either single or multiple doses. The pharmaceutical compositions according to the invention may be formulated with pharmaceutically acceptable carriers or diluents as well as any other known adjuvants and excipients in accordance with conventional techniques such as those disclosed in Remington: The Science and Practice of Pharmacy, 19th Edition, Gennaro, Ed., Mack Publishing Co., Easton, PA, 1995.
The pharmaceutical compositions may be specifically formulated for administration by any suitable route such as oral, rectal, nasal, pulmonary, topical (including buccal and sublingual), transdermal, intracisternal, intraperitoneal, vaginal and parentéral (including subcutaneous, intramuscular, intrathecal, intravenous and intradermal) routes. It wili be appreciated that the route wili dépend on the general condition and âge of the subject to be treated, the nature of the condition to be treated and the active ingrédient.
Pharmaceutical compositions for oral administration include solid dosage forms such as capsules, tablets, dragees, pills, lozenges, powders and granules. Where appropriate, the compositions may be prepared with coatings such as enteric coatings or they may be formulated so as to provide controlled release of the active ingrédient such as sustained or prolonged release according to methods well known in the art. Liquid dosage forms for oral administration include solutions, émulsions, suspensions, syrups and élixirs.
Pharmaceutical compositions for parentéral administration include stérile aqueous and nonaqueous injectable solutions, dispersions, suspensions or émulsions as well as stérile powders to be reconstituted in stérile injectable solutions or dispersions prior to use. Other suitable administration forms include, but are not limited to, suppositories, sprays, ointments, creams, gels, inhalants, dermal patches and implants.
Typical oral dosages range from about 0.001 to about 100 mg/kg body weight per day. Typical oral dosages also range from about 0.01 to about 50 mg/kg body weight per day. Typical oral dosages further range from about 0.05 to about 10 mg/kg body weight per day. Oral dosages are usually administered in one or more dosages, typically, one to three dosages per day. The exact dosage wili dépend upon the frequency and mode of administration, the sex, âge, weight and general condition of the subject treated, the nature and severity of the condition treated and any concomitant diseases to be treated and other factors évident to those skilled in the art.
The formulations may also be presented in a unit dosage form by methods known to those skilled in the art. For illustrative purposes, a typical unit dosage form for oral administration may contain from about 0.01 to about 1000 mg, from about 0.05 to about 500 mg, or from about 0.5 mg to about 200 mg.
For parentéral routes such as intravenous, intrathecal, intramuscular and similar administration, typical doses are in the order of half the dose employed for oral administration.
The présent invention also provides a process for making a pharmaceutical composition comprising mixing a therapeutically effective amount of a compound of formula (I) and at least one pharmaceutically acceptable carrier or diluent. In an embodiment, of the présent invention, the compound utilized in the aforementioned process is one of the spécifie compounds disclosed in the Experimental Section herein.
The compounds of this invention are generally utilized as the free substance or as a pharmaceutically acceptable sait thereof. One example is an acid addition sait of a compound having the utility of a free base. When a compound of formula (I) contains a free base such salts are prepared in a conventional manner by treating a solution or suspension of a free base of formula (I) with a molar équivalent of a pharmaceutically acceptable acid. Représentative examples of suitable organic and inorganic acids are described above.
For parentéral administration, solutions of the compounds of formula (I) in stérile aqueous solution, aqueous propylene glycol, aqueous vitamin E or sesame or peanut oil may be employed. Such aqueous solutions should be suitably buffered if necessary and the liquid diluent first rendered isotonie with sufficient saline or glucose. The aqueous solutions are particularly suitable for intravenous, intramuscular, subeutaneous and intraperitoneal administration. The compounds of formula (I) may be readily incorporated into known stérile aqueous media using standard techniques known to those skilled in the art.
Suitable pharmaceutical carriers include inert solid diluents or fillers, stérile aqueous solutions and various organic solvents. Examples of solid carriers include lactose, terra alba, sucrose, cyclodextrin, talc, gelatin, agar, pectin, acacia, magnésium stéarate, stearic acid and lower alkyl ethers of cellulose. Examples of liquid carriers include, but are not limited to, syrup, peanut oil, olive oil, phospholipids, fatty acids, fatty acid amines, polyoxyethylene and water. Similarly, the carrier or diluent may include any sustained release material known in the art, such as glyceryl monostearate or glyceryl distearate, alone or mixed with a wax. The pharmaceutical compositions formed by combining the compounds of formula (I) and a pharmaceutically acceptable carrier are then readily administered in a variety of dosage forms suitable for the disclosed routes of administration. The formulations may conveniently be presented in unit dosage form by methods known in the art of pharmacy.
Formulations of the présent invention suitable for oral administration may be presented as discrète units such as capsules or tablets, each containing a predetermined amount of the active ingrédient, and optionally a suitable excipient. Furthermore, the orally available formulations may be in the form of a powder or granules, a solution or suspension in an aqueous or non-aqueous liquid, or an oil-in-water or water-in-oil liquid émulsion.
If a solid carrier is used for oral administration, the préparation may be tabletted, placed in a hard gelatin capsule in powder or pellet form or it may be in the form of a troche or lozenge. The amount of solid carrier will vary widely but will range from about 25 mg to about 1 g per dosage unit. If a liquid carrier is used, the préparation may be in the form of a syrup, émulsion, soft gelatin capsule or stérile injectable liquid such as an aqueous or non-aqueous liquid suspension or solution.
The pharmaceutical compositions of the invention may be prepared by conventional methods in the art. For example, tablets may be prepared by mixing the active ingrédient with ordinary adjuvants and/or diluents and subsequently compressing the mixture in a conventional tableting machine préparé tablets. Examples of adjuvants or diluents comprise: corn starch, potato starch, talcum, magnésium stéarate, gelatin, lactose, gums, and the like. Any other adjuvants or additives usually used for such purposes such as colorings, flavorings, preservatives etc. may be used provided that they are compatible with the active ingrédients.
TREATMENT OF DISORDERS
As mentioned above, the compounds of formula (I) are PDE1 enzyme inhibitors and as such are useful to treat associated neurological and psychiatrie disorders.
The invention thus provides a compound of formula (I) or a pharmaceutically acceptable acid addition sait thereof, as well as a pharmaceutical composition containing such a compound, for use in the treatment of a neurodegenerative disorder, psychiatrie disorder or drug addiction in mammals including humans; wherein the neurodegenerative disorder is selected from the group consisting of Alzheimer's disease, multi-infarct dementia, alcoholic dementia or other drugrelated dementia, dementia associated with intracranial tumors or cérébral trauma, dementia associated with Huntington's disease or Parkinson's disease, or AIDS-related dementia; delirium; amnestic disorder; post-traumatic stress disorder; mental retardation; a learning disorder, for example reading disorder, mathematics disorder, or a disorder of written expression; attention-deficit/hyperactivity disorder; and age-related cognitive décliné; and wherein the psychiatrie disorder is selected from the group consisting of schizophrenia, for example of the paranoid, disorganized, catatonie, undifferentiated, or residual type; schizophreniform disorder; schizoaffective disorder, for example of the delusional type or the dépressive type; delusional disorder; substance-induced psychotic disorder, for example psychosis induced by alcohol, amphétamine, cannabis, cocaïne, hallucinogens, inhalants, opioids, or phencyclidine; personality disorder of the paranoid type; and personality disorder of the schizoid type; and wherein the drug addiction is an alcohol, amphétamine, cocaïne, or opiate addiction.
The compounds of formula (I) or pharmaceutically acceptable salts thereof may be used in combination with one or more other drugs in the treatment of diseases or conditions for which the compounds of the présent invention hâve utility, where the combination of the drugs together are safer or more effective than either drug alone. Additionally, the compounds of the présent invention may be used in combination with one or more other drugs that treat, prevent, control, ameliorate, or reduce the risk of side effects or toxicity of the compounds of the présent invention. Such other drugs may be administered, by a route and in an amount commonly used therefore, contemporaneously or sequentially with the compounds of the présent invention. Accordingly, the pharmaceutical compositions of the présent invention include those that contain one or more other active ingrédients, in addition to the compounds of the présent invention. The combinations may be administered as part of a unit dosage form combination product, or as a kit or treatment protocol wherein one or more additional drugs are administered in separate dosage forms as part of a treatment regimen.
The présent invention provides a method of treating a mammal, including a human, suffering from a neurodegenerative disorder selected from a cognition disorder or movement disorder, which method comprises administering to the subject a therapeutically effective amount of a compound of formula (I).
This invention further provides a method of treating a neurodegenerative disorder or condition in a mammal, including a human, which method comprises administering to said mammal an amount of a compound of formula (I) effective in inhibiting PDE1.
This invention also provides a method of treating a subject suffering from a psychiatrie disorder, which method comprises administering to the subject a therapeutically effective amount of a compound of formula (I). Examples of psychiatrie disorders that can be treated according to the présent invention include, but are not limited to, Attention Déficit Hyperactivity Disorder (ADHD) schizophrenia, for example ofthe paranoid, disorganized, catatonie, undifferentiated, or residual type; schizophreniform disorder; schizoaffective disorder, for example of the delusional type or the dépressive type; delusional disorder; substance-induced psychotic disorder, for example psychosis induced by alcohol, amphétamine, cannabis, cocaïne, hallucinogens, inhalants, opioids, or phencyclidine; personality disorder of the paranoid type; and personality disorder of the schizoid type; and the anxiety disorder is selected from panic disorder; agoraphobia; a spécifie phobia; social phobia; obsessive-compulsive disorder; post-traumatic stress disorder; acute stress disorder; and generalized anxiety disorder.
It has been found that the compounds of formula (I) or pharmaceutically acceptable salts thereof may advantageously be administered in combination with at least one neuroleptic agent (which may be a typical or an atypical antipsychotic agent) to provide improved treatment of psychiatrie disorders such as schizophrenia. The combinations, uses and methods of treatment of the invention may also provide advantages in treatment of patients who fail to respond adequately or who are résistant to other known treatments.
The présent invention thus provides a method of treating a mammal suffering from a psychiatrie disorder, such as schizophrenia, which method comprises administering to the mammal a therapeutically effective amount of a compound of formula (I), either alone or as combination therapy together with at least one neuroleptic agent.
The term neuroleptic agent as used herein refers to drugs, which hâve the effect on cognition and behaviour of antipsychotic agent drugs that reduce confusion, delusions, hallucinations, and psychomotor agitation in patients with psychoses. Also known as major tranquilizers and antipsychotic drugs, neuroleptic agents include, but are not limited to: typical antipsychotic drugs, including phenothiazines, further divided into the aliphatics, piperidines, and piperazines, thioxanthenes (e.g., cisordinol), butyrophenones (e.g., haloperidol), dibenzoxazepines (e.g., loxapine), dihydroindolones (e.g., molindone), diphenylbutylpiperidines (e.g., pimozide), and atypical antipsychotic drugs, including benzisoxazoles (e.g., rispéridone), sertindole, olanzapine, quetiapine, osanetant and ziprasidone.
Particularly preferred neuroleptic agents for use in the invention are sertindole, olanzapine, rispéridone, quetiapine, aripiprazole, haloperidol, clozapine, ziprasidone and osanetant.
The présent invention further provides a method of treating a subject suffering from a cognition disorder, which method comprises administering to the subject a therapeutically effective amount of a compound of formula (I). Examples of cognition disorders that can be treated according to the présent invention include, but are not limited to, Alzheimer's disease, multiinfarct dementia, alcoholic dementia or other drug-related dementia, dementia associated with intracranial tumors or cérébral trauma, dementia associated with Huntington's disease or Parkinson's disease, or AIDS-related dementia; delirium; amnestic disorder; post-traumatic stress disorder; mental retardation; a learning disorder, for example reading disorder, mathematics disorder, or a disorder of written expression; attention-deficit/hyperactivity disorder; and age-related cognitive décliné.
This invention also provides a method of treating a movement disorder, which method comprises administering to the subject a therapeutically effective amount of a compound of formula (I). Examples of movement disorders that can be treated according to the présent invention include, but are not limited to, Huntington's disease and dyskinesia associated with dopamine agonist therapy. This invention further provides a method of treating a movement disorder selected from Parkinson's disease and restless leg syndrome, which comprises administering to the subject a therapeutically effective amount of a compound of formula (I).
This invention also provides a method of treating a mood disorder, which method comprises administering to the subject a therapeutically effective amount of a compound of formula (I). Examples of mood disorders and mood épisodes that can be treated according to the présent invention include, but are not limited to, major dépressive épisode ofthe mild, moderate or severe type, a manie or mixed mood épisode, a hypomanie mood épisode; a dépressive épisode with a typical features; a dépressive épisode with melancholic features; a dépressive épisode with catatonie features; a mood épisode with postpartum onset; post-stroke dépréssion; major dépressive disorder; dysthymie disorder; minor dépressive disorder; premenstrual dysphorie disorder; post-psychotic dépressive disorder of schizophrenia; a major dépressive disorder superimposed on a psychotic disorder such as delusional disorder or schizophrenia; a bipolar disorder, for example bipolar I disorder, bipolar II disorder, and cyclothymie disorder. It is understood that a mood disorder is a psychiatrie disorder.
This invention further provides a method of treating a disorder comprising as a symptom a deficiency in attention and/or cognition in a mammal, including a human, which method comprises administering to said mammal an amount of a compound of formula (I) effective in treating said disorder.
Other disorders that can be treated according to the présent invention are obsessive/compulsive disorders, Tourette's syndrome and other tic disorders.
As used herein, and unless otherwise indicated, a neurodegenerative disorder or condition refers to a disorder or condition that is caused by the dysfunction and/or death of neurons in the central nervous System. The treatment of these disorders and conditions can be facilitated by administration of an agent which prevents the dysfunction or death of neurons at risk in these disorders or conditions and/or enhances the function of damaged or healthy neurons in such a way as to compensate for the loss of function caused by the dysfunction or death of at-risk neurons. The term neurotrophic agent as used herein refers to a substance or agent that has some or ail of these properties.
Examples of neurodegenerative disorders and conditions that can be treated according to the présent invention include, but are not limited to, Parkinson's disease; Huntington's disease; dementia, for example Alzheimer's disease, multi-infarct dementia, AIDS-related dementia, and Fronto temperal Dementia; neurodegeneration associated with cérébral trauma; neurodegeneration associated with stroke, neurodegeneration associated with cérébral infarct;
hypoglycemia-induced neurodegeneration; neurodegeneration associated with epileptic seizure; neurodegeneration associated with neurotoxin poisoning; and multi-system atrophy.
In one embodiment of the présent invention, the neurodegenerative disorder or condition involves neurodegeneration of striatal medium spiny neurons in a mammal, including a human.
In a further embodiment of the présent invention, the neurodegenerative disorder or condition is Huntington's disease.
Ail référencés, including publications, patent applications and patents, cited herein are hereby incorporated by reference in their entirety and to the same extent as if each reference were individually and specifically indicated to be incorporated by reference and were set forth in its entirety (to the maximum extent permitted by law).
Headings and sub-headings are used herein for convenience only, and should not be construed as limiting the invention in any way.
The use of any and ail examples, or exemplary language (including “for instance”, “for example”, “e.g.”, and “as such”) in the présent spécification is intended merely to better illuminate the invention, and does not pose a limitation on the scope of invention unless otherwise indicated.
The citation and incorporation of patent documents herein is done for convenience only, and does not reflect any view of the validity, patentability and/or enforceability of such patent documents.
The présent invention includes ail modifications and équivalents of the subject-matter recited in the daims appended hereto, as permitted by applicable law.
COMPOUNDS OFTHE INVENTION
Compound number | Compound | PDE1C IC50 (nM) | PDE1B IC50 (nM) | PDE1A IC50 (nM) |
1 | 7,8-Dimethoxy-N(tetrahydrofuran-3yl)quinazolin-4-amine | 590 | 230 | 1200 |
1 Stereoisomer 1 | 7,8-Dimethoxy-N(tetrahydrofuran-3yl)quinazolin-4-amine | 280 | 54 | 280 |
Compound number | Compound | PDE1C IC50 (nM) | PDE1B IC50 (nM) | PDE1A IC50 (nM) |
1 Stereoisomer 2 | 7,8-Dimethoxy-N(tetrahydrofuran-3yl)quinazolin-4-amine | 1200 | 600 | 1900 |
2 | trans-N-(-2cyclopropyltetrahydrofuran-3yl)-7,8-dimethoxyquinazolin-4amine | 1300 | 260 | 2400 |
3 Stereoisomer 1 | 7,8-dimethoxy-N-(-2m ethyltetrahyd rof u ra n-3yl)quinazolin-4-amine | 3000 | 1200 | 2500 |
3 Stereoisomer 2 | 7,8-dimethoxy-N-(-2m ethyltetra hyd rof u ra n-3yl)quinazolin-4-amine | 310 | 94 | 490 |
3 Stereoisomer 3 | 7,8-dimethoxy-N-(-2m ethyltetra hyd rofu ra n-3yl)quinazolin-4-amine | 390 | 100 | 890 |
3 Stereoisomer 4 | 7,8-dimethoxy-N-(-2methyltetrahydrofuran-3yl)quinazolin-4-amine | 270 | 120 | 580 |
4 | (7,8-dimethoxy-N-methyl-N- (tetrahydrofuran-3- yl)quinazolin-4-amine | 140 | 84 | 360 |
4 Stereoisomer 1 | (R)-7,8-dimethoxy-N-methylN-(tetra hyd rofu ran-3yl)quinazolin-4-amine | 140 | 80 | 370 |
4 Stereoisomer 2 | (S)-7,8-dimethoxy-N-methyl- N-(tetrahydrofuran-3- yl)quinazolin-4-amine | 140 | 80 | 1400 |
5 | N-(2,3- dimethyltetrahydrofuran-3-yl)7,8-dimethoxyquinazolin-4amine | 130 | 33 | 130 |
Compound number | Compound | PDE1C IC50 (nM) | PDE1B IC50 (nM) | PDE1A IC50 (nM) |
5 Stereoisomer 1 | N-(2,3- d i m ethyltetra hyd rof u ran-3-yl )- 7,8-dimethoxyquinazolin-4- amine | 1100 | 300 | 590 |
5 Stereoisomer 2 | N-(2,3- d i methyltetra hyd rof ura n-3-y I )- 7,8-dimethoxyquinazolin-4- amine | 400 | 87 | 240 |
5 Stereoisomer 3 | N-(2,3- d i m ethyltetra hyd rof u ra n-3-yl )- 7,8-dimethoxyquinazolin-4amine | 67 | 6 | 33 |
5 Stereoisomer 4 | N-(2,3dimethyltetrahydrofuran-3-yl)7,8-dimethoxyquinazolin-4amine | 140 | 15 | 77 |
6 | 7,8-dimethoxy-N-(3methyltetra- hydrofuran-3yl)quinazolin-4-amine | 160 | 62 | 150 |
6 stereoisomer 1 | 7,8-dimethoxy-N-(3methyltetra-hydrofuran-3yl)quinazolin-4-amine | 400 | 110 | 290 |
6 Stereoisomer 2 | 7,8-dimethoxy-N-(3methyltetra- hydrofuran-3yl)quinazolin-4-amine | 110 | 37 | 140 |
7 | (S)-7,8-dimethoxy-N- (tetrahydrofuran-3- yl)quinazolin-4-amine | n.d. | n.d. | n.d. |
8 | (S)-N-ethyl-7,8-dimethoxy-N(tetrahydrofuran-3yl)quinazolin-4-amine | 510 | 250 | 480 |
Compound number | Compound | PDE1C IC50 (nM) | PDE1B IC50 (nM) | PDE1A IC50 (nM) |
9 | (S)-7,8-dimethoxy-N-propyl-N(tetrahydrofuran-3yl)quinazolin-4-amine | 540 | 180 | 280 |
10 | (S)-N-benzyl-7,8-dimethoxy- N-(tetrahydrofuran-3- yl)quinazolin-4-amine | 1400 | 360 | 820 |
11 | (S)-N-(cyclopropylmethyl )-7,8dimethoxy-N-(tetrahydrofuran3-yl)quinazolin-4-amine | 1600 | 420 | 850 |
12 | (R)-7,8-dimethoxy-N- (tetrahydrofuran-3- yl)quinazolin-4-amine | n.d. | n.d. | n.d. |
13 | (R)-N-ethyl-7,8-dimethoxy-N- (tetrahydrofuran-3- yl)quinazolin-4-amine | 1500 | 600 | 1200 |
14 | (R)-7,8-dimethoxy-N-propylN-(tetra hyd rofu ra n-3yl)quinazolin-4-amine | 360 | 180 | 270 |
15 | (R)-N-(cyclopropylmethyl)-7,8dimethoxy-N-(tetrahydrofuran3-yl)quinazolin-4-amine | 2100 | 820 | 2500 |
16 | (R)-N-benzyl-7,8-dimethoxy- N-(tetrahydrofuran-3- yl)quinazolin-4-amine | 1600 | 410 | 1200 |
17 | trans-7,8-dimethoxy-N-4methoxytetrahydrofuran-3yl)quinazolin-4-amine | 1300 | 520 | 2200 |
18 | trans-4-((7,8dimethoxyquinazolin-4yl)amino)tetrahydrofuran-3-ol | 2600 | 1300 | 2300 |
19 | cis-4-((7,8dimethoxyquinazolin-4y I )am i no )tetra hyd rofu ra n-3-ol | n.d. | 840 | 4600 |
Compound number | Compound | PDE1C IC50 (nM) | PDE1B IC50 (nM) | PDE1A IC50 (nM) |
20 Stereoisomer 1 | N-(2,3- Dimethyltetrahydrofuran-3-yl)- 7,8-dimethoxy-N- methylquinazolin-4-amine | 33 | 5 | 19 |
20 Stereoisomer 2 | N-(2,3- Dimethyltetrahydrofuran-3-yl)- 7,8-dimethoxy-N- methylquinazolin-4-amine | 27 | 4 | 26 |
20 Stereoisomer 3 | N-(2,3- Di m ethyltetra hyd rof u ran-3-yl )7,8-dimethoxy-Nmethylquinazolin-4-amine | 890 | 190 | 440 |
20 Stereoisomer 4 | N-(2,3- D i m ethyltetra hyd rof u ra n-3-yl )7,8-dimethoxy-Nmethylquinazolin-4-amine | 170 | 39 | 120 |
21 Stereoisomer 1 | N-(2,2- d i m ethyltetra hyd rof u ra n-3-yl )7,8-dimethoxyquinazolin-4amine | 2800 | 780 | 1500 |
21 Stereoisomer 2 | N-(2,2- dimethyltetrahydrofuran-3-yl)- 7,8-dimethoxyquinazolin-4- amine | 1600 | 260 | 1300 |
22 Stereoisomer 1 | 7,8-dimethoxy-N-methyl-N-(2m ethyltetra hyd rof u ra n-3yl)quinazolin-4-amine | 79 | 28 | 110 |
22 Stereoisomer 2 | 7,8-dimethoxy-N-methyl-N-(2methyltetrahydrofuran-3yl)quinazolin-4-amine | 55 | 35 | 210 |
22 Stereoisomer 3 | 7,8-dimethoxy-N-methyl-N-(2m ethyltetra hyd rof u ra n-3yl)quinazolin-4-amine | 1500 | 430 | 1100 |
Compound number | Compound | PDE1C IC50 (nM) | PDE1B IC50 (nM) | PDE1A IC50 (nM) |
22 Stereoisomer 4 | 7,8-dimethoxy-N-methyl-N-(2methyltetrahydrofuran-3yl)quinazolin-4-amine | 780 | 1100 | 1500 |
23 Stereoisomer 1 | 7,8-dimethoxy-N-methyl-N-(3methyltetrahydrofuran-3yl)quinazolin-4-amine | 500 | 70 | 240 |
23 Stereoisomer 2 | 7,8-dimethoxy-N-methyl-N-(3m ethyltetra hyd rof u ra n-3yl)quinazolin-4-amine | 170 | 55 | 160 |
24 | /V-(3-Ethyltetrahydrofuran-3yl)-7,8-dimethoxyquinazolin-4amine | n.d. | n.d. | n.d. |
25 | Λ/-(2- Cyclopropyltetrahydrofuran-3yl)-7,8-dimethoxyquinazolin-4amine | 1300 | 260 | 2400 |
Table 1: Compounds ofthe invention; n.d. means “not determined”
EXPERIMENTAL SECTION
PREPARATION OF THE COMPOUNDS OF THE INVENTION
General Methods
Analytical LC-MS data were obtained using one of the methods identified below.
Method 1: A Waters Acquity UPLC-MS was used. Column: Acquity UPLC BEH C18 1.7pm; 2.1x50mm; Column température: 60 °C; Solvent System: A = water/trifluoroacetic acid (99.965:0.035) and B = acetonitrile /water/trifluoroacetic acid (94.965:5:0.035); Method: Linear gradient elution with 10 A:B = 90:10 to 0:100 in 1.0 minutes and with a flow rate of 1.2 mL/min.
Method 2: A Waters Acquity UPLC-MS was used. Column: Acquity UPLC BEH C18 1.7pm; 2.1x50mm; Column température: 60 °C; Solvent System: A = water/formic acid (99.9:0.1) and B = acetonitrile /water/formic acid (94.9:5:0.1); Method: Linear gradient elution with A:B = 90:10 to 0:100 in 1.0 minutes and with a flow rate of 1.2 mL/min.
Method 3: An Agitent 1200 LCMS System with ELS detector was used. Column: Agilent TC-C18 5 pm; 2.1x50mm; Column température: 50 °C; Solvent System: A = water/trifluoroacetic acid (99.9:0.1) and B = acetonitrile /trifluoroacetic acid (99.95:0.05); Method: Linear gradient elution with A:B = 99:1 to 0:100 in 4.0 minutes and with a flow rate of 0.8 mL/min.
Method 4: An Agilent 1200 LCMS System with ELS detector was used. Column: Agilent TC-C18 5 pm; 2.1x50mm; Column température: 50 °C; Solvent System: A = water/trifluoroacetic acid (99.9:0.1) and B = acetonitrile /trifluoroacetic acid (99.95:0.05); Method: Linear gradient elution with A:B = 90:10 to 0:100 in 4.0 minutes and with a flow rate of 0.8 mL/min.
Method 5: An Agilent 1200 LCMS System with ELS detector was used. Column: XBridge ShieldRP18, 5 pm, 50x2.1mm; Column température: 40 °C; Solvent System: A = water/NH3*H2O (99.95:0.05) and B = acetonitrile; Method: Linear gradient elution with A:B = 95:5 to 0:100 in 3.4 minutes and with a flow rate of 0.8 mL/min.
Method 6: An Agilent 1200 LCMS System with ELS detector was used. Column: XBridge ShieldRP18, 5 pm, 50x2.1mm; Column température: 40 °C; Solvent System: A = water/NH3*H2O (99.95:0.05) and B = acetonitrile; Method: Linear gradient elution with A:B = 99:1 to 0:100 in 3.4 minutes and with a flow rate of 0.8 mL/min.
Préparative LC-MS-purification was performed on a PE Sciex API 150EX instrument with atmospheric pressure chemical ionization. Column: 50 X 20 mm YMC ODS-A with 5 pm particle size; Solvent System: A = water/trifluoroacetic acid (99.965:0.035) and B = acetonitrile /water/trifluoroacetic acid (94.965:5:0.035); Method: Linear gradient elution with A:B = 80:20 to 0:100 in 7 minutes and with a flow rate of 22.7 mL/minute. Fraction collection was performed by split-flow MS détection.
Préparative SFC was performed on a Thar 80 instrument. Exemplified conditions can be, but not limited to: Column AD 250 X 30mm with 20 pm particle size; Column température: 38 °C, Mobile phase: Supercritical CO2/ EtOH(0.2%NH3H2O) =45/55.
Example 1
7,8-Dimethoxy-N-(tetrahydrofuran-3-y!)quinazolin-4-amine:
To a solution of 4-chloro-7,8-dimethoxyquinazoline (1.5 g, 6.7 mmol) in DMF (30 mL) was added tetrahydrofuran-3-amine (698 mg, 8.01 mmol), DIPEA (2.3 mL, 13 mmol). Nitrogen was bubbled through the mixture for 5 min. The reaction was then heated at 100 °C for 2 h. The crude mixture was evaporated and the residue was dissolved in ethyl acetate (20 mL), and filtered. The solid was washed with ethyl acetate (10 mL) to give 7,8-dimethoxy-N(tetrahydrofuran-3-yl)quinazolin-4-amine 1.4 g (76%).
The racemate of 7,8-dimethoxy-N-(tetrahydrofuran-3-yl)quinazolin-4-amine 1.4 g was purified by SFC séparation and numbered according to the order of elution:
Stereoisomer 1 (first eluting by SFC): 388 mg,
LC-MS (m/z) 276.1 (MH+) tR (minutes, method 3) = 1.82.
[a]20 D = -32 (c = 0.10 mg/mL, MeOH)
Stereoisomer 2 (second eluting by SFC): 413 mg
LC-MS (m/z) 276.1 (MH+) tR (minutes, method 3) = 1.81.
[a]2% = 23 (c = 0.10 mg/mL, MeOH)
Example 2
trans-N-(-2-cyclopropyltetrahydrofuran-3-yl)-7,8-dimethoxyquinazolin-4-amine: 4-Chloro-
7,8-dimethoxyquinazoline (200 mg, 0.890 mmol) and trans-2-cyclopropyl- tetrahydrofuran-3amine (170 mg, 1.34 mmol) were mixed in isopropanol (10 ml) and DIPEA (230 mg, 0.311 ml, 1.78 mmol). The reaction was heated in a microwave reactor for 40 min at 160 °C. After cooling to RT for a couple of hours a white precipitate was collected and dried overnight at 40 °C. Further purified by flash chromatography using a gradient of ethyl acetate and heptane to yield trans-N-(-2-cyclopropyltetrahydrofuran-3-yl)-7,8-dimethoxyquinazolin-4-amine 80 mg (29%).
LC-MS (m/z) 316.0 (MH+), tR (minutes, method 2) = 0.36.
Example 3
7,8-Dimethoxy-N-(-2-methyltetrahydrofuran-3-yl)quinazoIin-4-amine:
To a solution of 2-methyltetrahydrofuran-3-amine 2,2,2-trifluoroacetate (9.6 g, 45 mmol), 4chloro-7,8-dimethoxyquinazoline (5.0 g, 22 mmol) in DMF (200 mL) was added DIPEA(14.4 g, 111 mmol). The mixture was stirred at 120 °C overnight. The mixture was concentrated and the residue purified by prep-HPLC to afford 1.2 g (19%) of 7,8-dimethoxy-N-(-2methyltetrahydrofuran-3-yl)quinazolin-4-amine as a white solid.
A mixture of ail possible stereoisomers of 7,8-dimethoxy-N-(-2-methyltetrahydrofuran-3yl)quinazolin-4-amine (1.43 g, 4.90 mmol) was purified by SFC séparation and numbered according to their order of elution:
Stereoisomer 1 (first eluting by SFC): 213 mg,
LC-MS (m/z) 290.1 (MH+).
[o]20d = 21 (c = 0.1 mg/mL, MeOH)
Stereoisomer 2 (second eluting by SFC): 141 mg,
LC-MS (m/z) 290.1 (MH+).
[o]20d = -24 (c = 0.1 mg/mL, MeOH)
Stereoisomer 3 (third eluting by SFC): 58 mg,
LC-MS (m/z) 290.1 (MH+).
[α]2% = 65 (c = 0.1 mg/mL, MeOH)
Stereoisomer 4 (fourth eluting by SFC): 132 mg,
LC-MS (m/z) 290.1 (MH+).
[a]20 D = -54 (c = 0.1 mg/mL, MeOH)
7,8-Dimethoxy-N-methyl-N-(tetrahydrofuran-3-yl)quinazolin-4-amine: 4-Chloro-7,8dimethoxyquinazoline (200 mg, 0.890 mmol) and N-methyltetrahydrofuran-3-amine (180 mg,
1.78 mmol) were mixed in isopropanol (10 ml) and DIPEA (575 mg, 0.78 ml, 4.5 mmol). The mixture was heated in a microwave oven for 30 min at 150 °C. The reaction mixture was poured into H2O (20 mL), extracted with ethyl acetate (3x20 mL), the combined organic phases were washed with brine, dried over MgSO4 and concentrated in vacuo. The crude product was purified by flash chromatography using a gradient of ethyl acetate and ethyl acetate + 5% methanol to yield 7,8-dimethoxy-N-methyl-N-(tetrahydrofuran-3-yl)quinazolin-4-amine 140 mg (54%).
LC-MS (m/z) 290.3 (MH+), tR (minutes, method 1) = 0.34.
(R)-7,8-dimethoxy-N-methyl-N-(tetrahydrofuran-3-yl)quinazolin-4-amine:
To a solution of (R)-7,8-dimethoxy-N-(tetrahydrofuran-3-yl)quinazolin-4-amine (390 mg, 1.42 mmol) in THF (20 mL) was added NaH (283 mg, 7.08 mmol, 60%) at 0 °C, and the mixture was stirred at 0 °C for 10 min. To the solution was added methyl iodide (1.0 g, 7.1 mmol) at 0°C. The reaction was allowed to warm 20°C and stirred for 2 hours. The solution was quenched with sat. aq. NH4CI (0.3mL), and concentrated under vacuum. The residue was diluted with ethyl acetate (50 mL), washed with brine, dried and concentrated under vacuum. The residue was purified by flash chromatography on silica gel (ethyl acetate/petroleum ether =1/10 to 2/1) to give (R)-7,8-dimethoxy-N-methyl-N-(tetrahydrofuran-3-yl)quinazolin-4-amine 400 mg (97%) as a white solid
LC-MS (m/z) 290.1 (MH+), tR (minutes, method 6) = 1.753.
[a]2% = 19 (c = 0.1 mg/mL, CHCI3)
Stereoisomer 2 ^0 (S)-7,8-dimethoxy-N-methyl-N-(tetrahydrofuran-3-yl)quinazolin-4-amine:
To a solution of (R)-7,8-dimethoxy-N-(tetrahydrofuran-3-yl)quinazolin-4-amine (420 mg, 1.52 mmol) in THF (20 mL) was added NaH (305 mg, 7.63 mmol, 60%) at 0°C. The reaction was stirred at 0°C for 10 min. Methyl iodide (1.08 g, 7.63 mmol) was added at 0°C and the mixture allowed to warm to 20°C and stirred for 2 hours. The solution was quenched with sat.aq. NH4CI (0.3 mL), and concentrated under vacuum. The residue was diluted with ethyl acetate (50 mL), washed with brine, dried and concentrated under vacuum. The residue was purified by flash chromatography on silica gel (eluted ethylacetate/petroleum ether=1/10 to 2/1) to give (S)-7,8dimethoxy-N-methyl-N-(tetrahydrofuran-3-yl)quinazolin-4-amine 410 mg (93%) as a white solid. LC-MS (m/z) 290.1 (MH+), tR (minutes, method 6) = 1.767.
[a]20 D = -21 (c = 0.1 mg/mL, CHCI3)
Example 5
N-(2,3-dimethyltetrahydrofuran-3-yl)-7,8-dimethoxyquinazolin-4-amine: A mixture of 4chloro-7,8-dimethoxyquinazoline (8.4 g, 37 mmol), 2,3-dimethyltetrahydrofuran-3-amine (4.0 g, 35 mmol) and NaHCO3 (2.6 g, 31 mmol) in DMSO (120 mL) was stirred at 100 °C for 12 hours. The solution was poured into ice-water (200 mL), extracted with DCM (3x100 mL). The combined organic phases were washed with brine (3x10 mL), dried over Na2SO4 and concentrated in vacuo. The residue was purified by flash chromatography on silica gel using a gradient of ethyl acetate and petroleum ether to give N-(2,3-dimethyltetrahydrofuran-3-yl)-7,8dimethoxyquinazolin-4-amine 4.0 g (43%) as a white solid.
A mixture of ail possible stereoisomers of N-(2,3-dimethyltetrahydrofuran-3-yl)-7,8dimethoxyquinazolin-4-amine 6.0 g was purified by SFC séparation and numbered according to their order of elution:
Stereoisomer 1 (first eluting by SFC): 536 mg,
LC-MS (m/z) 304.1 (MH+) tR (minutes, method 3) = 1.98.
[a]2% = 25 (c = 0.10 mg/mL, MeOH)
Stereoisomer 2 (second eluting by SFC): 546 mg,
LC-MS (m/z) 304.1 (MH+) tR (minutes, method 3) = 1.98.
[a]20o = -14 (c = 0.10 mg/mL, MeOH)
Stereoisomer 3 (third eluting by SFC): 920 mg,
LC-MS (m/z) 304.1 (MH+) tR (minutes, method 3) = 2.00.
[a]20o = 22 (c = 0.10 mg/mL, MeOH)
Stereoisomer 4 (fourth eluting by SFC): 999 mg,
LC-MS (m/z) 304.1 (MH+) tR (minutes, method 3) = 2.00.
[a]20 D = -20 (c = 0.1 mg/mL, MeOH)
Example 6
7.8- Dimethoxy-N-(3-methyltetrahydrofuran-3-yl)quinazolin-4-amine: 4-Chloro-7,8dimethoxyquinazoline (200 mg, 0.890 mmol) and 3-methyltetrahydrofuran-3-amine (90 mg, 0.890 mmol) were mixed in isopropanol (10 mL) and DIPEA (345 mg, 466 pl, 2.67 mmol). The reaction was heated for 2 hours at 170 °C in a microwave oven. Conversion not complété as judged by LCMS. 3-Methyltetrahydrofuran-3-amine (90 mg, 0.89 mmol) was then added and mixture heated for 40 min at 170 °C in a microwave oven. The reaction mixture was poured into H2O (20 mL) and extracted with ethyl acetate (3x20mL). The combined organic phases were washed with brine, dried over MgSO4 and concentrated in vacuo. The crude product was purified by flash chromatography using a gradient of ethyl acetate and heptane yielding 7,8dimethoxy-N-(3-methyltetrahydrofuran-3-yl)quinazolin-4-amine 63 mg, (23%).
LC-MS (m/z) 290.2 (MH+), tR (minutes, method 2) = 0.33.
7.8- Dimethoxy-N-(3-methyltetrahydrofuran-3-yl)quinazolin-4-amine (900 mg, 0.35 mmol) was purified by SFC séparation
The pure fractions were collected and solvent was evaporated under vacuum to afford
Stereoisomer 1 (first eluting by SFC): 400 mg (44%).
LC-MS (m/z) 290.1 (MH+), tR (minutes, method 3) = 1.945, ee% = 98.9%.
[a]2% = 11.67 (c = 0.1 mg/mL, MeOH)
Stereoisomer 2 (second eluting by SFC): 400 mg (44%).
LC-MS (m/z) 290.1 (MH+), tR (minutes, method 3) = 1.951, ee% = 97.7%.
[a]20 D = -12.00 (c = 0.1 mg/mL, MeOH)
Example 7
Ο (S)-7,8-Dimethoxy-N-(tetrahydrofuran-3-yl)quinazolin-4-amine: A solution of 4-chloro-7,8dimethoxyquinazoline (1.5 g, 6.7 mmol), (S)-tetrahydrofuran-3-amine hydrochloride (1.00 g, 8.00 mmol) and DIPEA (3.44 g, 26.7 mmol) in DMF (20 mL) was stirred at 100 °Cfor 3 hours. The solution was concentrated under vacuum. The residue was diluted with DCM (300 mL) and washed with brine (3x50 mL). The organic layer was evaporated and the residue was purified by prep-HPLC to afford (S)-7,8-dimethoxy-N-(tetrahydrofuran-3-yl)quinazolin-4-amine 1.2 g (67%) as a white solid
Example 8 (S)-N-ethyl-7,8-dimethoxy-N-(tetrahydrofuran-3-yl)quinazolin-4-amine:
To a solution of (S)-7,8-dimethoxy-N-(tetrahydrofuran-3-yl)quinazolin-4-amine (200 mg, 0.73 mmol) in THF (2 mL) was added NaH (60%, 58 mg, 2.4 mmol) at 0°C, then it was stirred at 0°C for 10 min. lodoethane (135 mg, 0.87 mmol) was added at 0°C and the reaction was warmed to 20°C and stirred 12 hours. The solution was quenched with sat. aq. NH4CI (0.3mL), and concentrated under vacuum. The residue was diluted with ethylacetate (50 mL), washed with brine, dried and concentrated under vacuum. The residue was purified by flash chromatography on silica gel (eluted ethylacetate/petroleum ether=1/10 to 2/1) to give the (S)-N-ethyl-7,8dimethoxy-N-(tetrahydrofuran-3-yl)quinazolin-4-amine 58 mg (26%) as a white solid.
LC-MS (m/z) 304.2 (MH+), tR (minutes, method 3) = 1.984.
Example 9
(S)-7,8-dimethoxy-N-propyl-N-(tetrahydrofuran-3-yl)quinazolin-4-amine:
To a solution of (S)-7,8-dimethoxy-N-(tetrahydrofuran-3-yl)quinazolin-4-amine (200 mg, 0.73 mmol) in THF (2 mL) was added NaH (60%, 58 mg, 2.4 mmol) at 0 °C, it was stirred at 0°C for 10 min. 1-lodopropane (148 mg, 0.87 mmol) was added to the reaction mixture at 0°C, then it was stirred at 20°C for 12 hours. The reaction was quenched with sat. aq. NH4CI (0.3 mL), and concentrated under vacuum. The residue was diluted with ethyl acetate (50 mL), washed with brine, dried and concentrated under vacuum. The residue was purified by préparative LC-MS to give (S)-7,8-dimethoxy-N-propyl-N-(tetrahydrofuran-3-yl)quinazolin-4-amine 40 mg (17%) as a white solid.
LC-MS (m/z) 318.2 (MH+), tR (minutes, method 3) = 2.176.
(S)-N-benzyl-7,8-dimethoxy-N-(tetrahydrofuran-3-yl)quinazolin-4-amine:
To a solution of (S)-7,8-dimethoxy-N-(tetrahydrofuran-3-yl)quinazolin-4-amine (200 mg, 0.73 mmol) in THF (2 mL) was added NaH (58 mg, 2.4 mmol, 60%) at 0°C, then it was stirred at 0°C for 10 min. benzylbromide (150 mg, 0.87 mmol) was added at 0°C, then it was stirred at 20°C for 12 hours. The reaction was quenched with sat. aq. NH4CI (0.3mL), and concentrated under vacuum. The residue was diluted with EA (50 mL), washed with brine, dried and concentrated under vacuum. The residue was purified by flash chromatography on silica gel using a gradient of ethyl acetate and heptane to give the (S)-N-benzyl-7,8-dimethoxy-N-(tetrahydrofuran-3yl)quinazolin-4-amine 60 mg (23%) as a white solid.
LC-MS (m/z) 366.2 (MH+), tR (minutes, method 4) = 1.640.
(S)-N-(cyclopropylmethyl)-7,8-dimethoxy-N-(tetrahydrofuran-3-yl)quinazolin-4-amine:
To a solution of (S)-7,8-dimethoxy-N-(tetrahydrofuran-3-yl)quinazolin-4-amine (100 mg, 0.36 mmol) in DMF (3 mL) was added NaH (100 mg, 2.5 mmol, 60%) at 0°C, then it was stirred at 0°C for 20 min. (bromomethyl)cyclopropane (58 mg, 0.44 mmol) was added at 0°C, then it was stirred at 20°C for 12 hours. The reaction was quenched with sat. aq. NH4CI (0.3mL), and concentrated under vacuum. The residue was diluted with ethyl acetate (50 mL), washed with brine, dried and concentrated under vacuum. The residue was purified by préparative LC-MS to give the (S)-N-(cyclopropylmethyl)-7,8-dimethoxy-N-(tetrahydrofuran-3-yl)quinazolin-4-amine 30 mg, (25%) as a white solid.
LC-MS (m/z) 330.0 (MH+), tR (minutes, method 3) = 1.834.
(R)-7,8-dimethoxy-N-(tetrahydrofuran-3-yl)quinazoIin-4-amine: A solution of 4-chloro-7,8dimethoxyquinazoline (1.5 g, 6.7 mmol), (R)-tetrahydrofuran-3-amine hydrochloride (1.00 g, 8.00 mmol) and DIPEA (3.44 g, 26.7mmol) in DMF (20 mL) was stirred at 100°C for 3 hours. The solution was concentrated under vacuum. The residue was diluted with DCM (300mL) washed with brine (3x50mL). The combined organic phases were evaporated and the residue was purified by prep-HPLC to afford (R)-7,8-dimethoxy-N-(tetrahydrofuran-3-yl)quinazolin-4amine 1.2 g (67%) as a white solid
Example 13
(R)-N-ethyl-7,8-dimethoxy-N-(tetrahydrofuran-3-yl)quinazolin-4-amine: To a solution of (R)-
7,8-dimethoxy-N-(tetrahydrofuran-3-yl)quinazolin-4-amine (100 mg, 0.36 mmol) in THF (5 mL) was added NaH 60% (44 mg, 1.82 mmol) at 0°C, then stirred at 0°C for 10 min. To the solution was added iodoethane (283 mg, 1.82 mmol) at 0°C, then stirred at 20°C for 12 hours. The solution was quenched with sat. aq. NH4CI (0.3mL), and concentrated under vacuum. The residue was diluted with ethyl acetate (50 mL), washed with brine, dried over MgSO4 and concentrated under vacuum. The residue was purified by flash chromatography on silica gel (eluent: ethyl acetate/petroleum ether=1/10 to 2/1) to give the (R)-N-ethyl-7,8-dimethoxy-N(tetrahydrofuran-3-yl)quinazolin-4-amine 36 mg (32%) as a white solid.
LC-MS (m/z) 304.1 (MH+), tR (minutes, method 5) = 1.720.
(R)-7,8-dimethoxy-N-propy]-N-(tetrahydrofuran-3-yl)quinazolin-4-amine: To a solution of (R)-7,8-dimethoxy-N-(tetrahydrofuran-3-yl)quinazolin-4-amine (100 mg, 0.36 mmol) in THF (5 mL) was added NaH 60% (44 mg, 1.82 mmol) at 0°C, then stirred at 0°C for 10 min. Then 1iodopropane (309 mg, 1.82 mmol) was added to the solution at 0°C, the reaction was stirred at 20°C for 12 hours. The solution was quenched with sat. aq. NH4CI (0.3 mL), and concentrated under vacuum. The residue was diluted with ethyl acetate (50mL), washed with brine, dried over MgSO4 and concentrated under vacuum. The residue was purified by flash chromatography on silica gel (eluent ethyl acetate/petroleum ether-=1/10 to 2/1) to give (R)-7,8-dimethoxy-N-propylN-(tetrahydrofuran-3-yl)quinazolin-4-amine 41 mg (35%) as a white solid.
LC-MS (m/z) 318.1 (MH+), tR (minutes, method 3) = 1.779.
Example 15
(R)-N-(cyclopropylmethyl)-7,8-dimethoxy-N-(tetrahydrofuran-3-yl)quinazolin-4-amine: Το a solution of (R)-7,8-dimethoxy-N-(tetrahydrofuran-3-yl)quinazolin-4-amine (100 mg, 0.36 mmol) in DMF (5 mL) was added NaH 60% (44 mg, 1.82 mmol) at 0°C, then stirred at 0°C for 20 min. Then (bromomethyl)cyclopropane (246 mg, 1.82 mmol) was added to the solution at 0°C, then stirred at 20°C for 12 hours. The solution was quenched with sat. aq. NH4CI (0.3mL), and concentrated under vacuum. The residue was diluted with ethyl acetate (50mL), washed with brine, dried over MgSO4 and concentrated under vacuum. The residue was purified prep-HPLC to give (R)-N-(cyclopropylmethyl)-7,8-dimethoxy-N-(tetrahydrofuran-3-yl)quinazolin-4-amine 36 mg (32%) as a white solid.
LC-MS (m/z) 330.1 (MH+), tR (minutes, method 3) = 1.816.
(R)-N-benzyl-7,8-dimethoxy-N-(tetrahydrofuran-3-yl)quinazolin-4-amine: To a solution of (R)-7,8-dimethoxy-N-(tetrahydrofuran-3-yl)quinazolin-4-amine (100 mg, 0.36 mmol) in THF (5 mL) was added NaH 60% (73 mg, 1.82 mmol) at 0°C, then stirred at 0°C for 10 min. Then benzylbromide (311 mg, 1.82 mmol) was added to the solution at 0°C, then stirred at 20°C for 12 hours. The solution was quenched with sat. aq. NH4CI (0.3mL), and concentrated under vacuum. The residue was diluted with ethyl acetate (50 mL), washed with brine, dried over MgSO4 and concentrated under vacuum. The residue was purified by flash chromatography on silica gel (eluent: ethyl acetate/petroleum ether=1/10 to 1/1) to give (R)-N-benzyl-7,8-dimethoxyN-(tetrahydrofuran-3-yl)quinazolin-4-amine 52 mg (45%) as a white solid.
LC-MS (m/z) 366.2 (MH+), tR (minutes, method 4) = 1.705.
Trans-7,8-dimethoxy-N-(4-methoxytetrahydrofuran-3-yl)quinazolin-4-amine:
4-Chloro-7,8-dimethoxyquinazoline (200 mg, 0.890 mmol) and trans-4-methoxytetrahydrofuran-
3-amine hydrochloride (164 mg, 1.07 mmol) were mixed in isopropanol (4 mL) and DIPEA (1270 pl, 7.27 mmol). The reaction was heated for 40 min at 160 °C under microwave irradiation. The reaction was poured into H2O (25 mL) and extracted with ethyl acetate (3x25 mL), the combined org. phases were washed with brine, dried over MgSO4 and concentrated in vacuo. Purified by flashchromatography using a gradient of heptane and ethyl acetate to yield trans-7,8dimethoxy-N-4-methoxytetrahydrofuran-3-yl)quinazolin-4-amine (220 mg, 0.721 mmol, 81 % yield).
LC-MS (m/z) 306.2 (MH+), tR (minutes, method 2) = 0.37.
trans-4-((7,8-dimethoxyquinazolin-4-yl)amino)tetrahydrofuran-3-ol:
4-Chloro-7,8-dimethoxyquinazoline (200 mg, 0.890 mmol) and 4-amino-tetrahydrofuran-3-ol hydrochloride (149 mg, 1.068 mmol) were mixed in isopropanol (3.6 mL) and DIPEA (1270 pl,
7.27 mmol). The mixture was heated in microwave oven for 40 min at 160 °C. The reaction was cooled to RT overnight, and the precipitate was isolated by filtration to yield trans-4-((7,8dimethoxyquinazolin-4-yl)amino)tetrahydrofuran-3-ol 214 mg (83 % yield)
LC-MS (m/z) 292.1 (MH+), tR (minutes, method 2) = 0.31.
Example 19
cis-4-((7,8-djmethoxyquinazolin-4-yl)amino)tetrahydrofuran-3-ol:
4-Chloro-7,8-dimethoxyquinazoline (200 mg, 0.890 mmol) and cis-4-amino-tetrahydrofuran-3-ol hydrochloride (149 mg, 1.07 mmol) were mixed in isopropanol (3.6 mL) and DIPEA (1270 pl,
7.27 mmol). The mixture was heated for 40 min at 160 °C in microwave oven. Cooled to RT and the solid precipitate was filtered of to yield cis-4-((7,8-dimethoxyquinazolin-4yl)amino)tetrahydrofuran-3-ol 224 mg (86%).
LC-MS (m/z) 292.1 (MH+), tR (minutes, method 2) = 0.31.
Example 20
N-(2,3-dimethyItetrahydrofuran-3-yl)-7,8-dimethoxy-N-methylquinazolin-4-amine:
To an ice-cold solution of N-(2,3-dimethyltetrahydrofuran-3-yl)-7,8-dimethoxy- quinazolin-4amine (example 5) (800 mg, 2.64 mmol), in THF (50 mL) was added NaH (160 mg, 3.97mmol, 60% in minerai oil). The mixture was allowed to warm to 20 °C and stirred for 30 min. Mel (560 mg, 3.97mmol) was added and the reaction was stirred for a further 3 hrs. The solution was quenched with sat. NH4CI (aq. 2mL) at 0 °C, and concentrated under vacuum. The residue was diluted with DCM (50 mL), washed with brine (3x5mL), dried and concentrated under vacuum. The residue was purified by flash chromatography on silica gel using a gradient of ethyl acetate and petroleum ether to give the N-(2,3-dimethyltetrahydrofuran-3-yl)-7,8-dimethoxy-Nmethylquinazolin-4-amine 580 mg (69%).
N-(2,3-Dimethyltetrahydrofuran-3-yl)-7,8-dimethoxy-N-methylquinazolin-4-amine 580 mg was purified by preparative-TLC (ethyl acetate/petroleum ether=2/1) to give racemic diastereomer 1
300 mg, (52%), and racemic diastereomer 2, 240 mg, (41%).
The racemate of diastereomer 1 (300 mg) was purified by SFC to afford:
Stereoisomer 1 (first eluting by SFC): 120 mg, (40%) 1H NMR (CDCI3 varian 400): δ 8.76 (s, 1 H), 7.71 (d, J =4.6 Hz, 1 H), 7.21 (d, J = 4.6 Hz, 1 H),
4.39- 4.36 (m, 1H), 4.09 (s, 3H), 4.03 (s, 3H), 3.92-3.89 (m, 1H), 3.85-3.81 (m, 1H), 3.22 (s, 3H), 2.56-2.49 (m, 1 H), 2.31-2.23 (m, 1H), 1.60 (s, 3H), 1.37 (d, J =3.2 Hz, 3H).
LC-MS (m/z) 318.2 (MH+) tR (minutes, method 3) = 2.01.
[a]D 20 -35 (c = 0.10, MeOH).
Stereoisomer 2 (second eluting by SFC): 120 mg, (40%).
1H NMR (CDCI3 varian 400): δ 8.75 (s, 1 H), 7.71 (d, J =4.6 Hz, 1 H), 7.21 (d, J = 4.6 Hz, 1 H),
4.39- 4.35 (m, 1H), 4.08 (s, 3H), 4.03 (s, 3H), 3.92-3.89 (m, 1H), 3.85-3.81 (m, 1H), 3.19 (s, 3H), 2.55-2.49 (m, 1H), 2.31-2.23 (m, 1H), 1.61 (s, 3H), 1.37 (d, J =3.0 Hz, 3H).
LC-MS (m/z) 318.2 (MH+) tR (minutes, method 3) = 2.00.
[a]D 20 +40 (c = 0.10, MeOH).
The racemate of diastereomer 2 (240 mg) was purified by SFC to afford:
Stereoisomer 3 (first eluting by SFC): 100 mg (42%), 1H NMR (CDCI3 varian 400): 5 8.67 (s, 1H), 7.71 (d, J =4.8 Hz, 1H), 7.18 (d, J = 4.8 Hz, 1H), 4.80-4.79 (m, 1H), 4.09 (s, 3H), 4.02 (s, 3H), 4.05-4.02 (m, 1H), 3.94-3.87 (m, 1H), 3.28 (s, 3H),
2.46- 2.38 (m, 1H), 2.18-2.14(m, 1H), 1.72 (s, 3H), 0.95 (d, J=3.2 Hz, 3H).
LC-MS (m/z) 318.2 (MH+) tR (minutes, method 3) = 1.99.
[a]D 20+10 (c = 0.10, MeOH).
Stereoisomer 4 (second eluting by SFC): 100 mg, (42%), 1H NMR (CDCI3 varian 400): 5 8.70 (s, 1H), 7.71 (d, J =4.8 Hz, 1H), 7.19 (d, J = 4.8 Hz, 1H), 4.83-4.78 (m, 1H), 4.09 (s, 3H), 4.02 (s, 3H), 4.06-4.02 (m, 1H), 3.94-3.87 (m, 1H), 3.30 (s, 3H),
2.47- 2.39 (m, 1 H), 2.18-2.14 (m, 1 H), 1.71 (s, 3H), 0.95 (d, J =3 Hz, 3H).
LC-MS (m/z) 318.2 (MH+) tR (minutes, method 3) = 1.99.
[a]D 20-10 (c = 0.10, MeOH).
N-(2,2-dimethyltetrahydrofuran-3-yl)-7,8-dimethoxyquinazolin-4-amine:
Step 1: To a solution of methyl 2-hydroxy-2-methylpropanoate (10 g, 185 mmol) in THF (120 mL) was added NaH 60% in minerai oil (3.4 g, 84.7 mmol) at 0°C. The mixture was allowed to warm to 20 °C and stirred for 30 minutes. The solvent was removed under vacuum. A solution of methyl acrylate (8.0 g, 93 mmol) in DMSO (100 mL) was added. The mixture was stirred at 20 °C for 30 minutes. A 6 M solution HCl (80 mL) was added. The mixture was extracted with MTBE (3x50 mL). The organic layer was washed with sat. aqueous NaHCO3 (40 mL), then brine (40 mL), dried over Na2SO4 and evaporated under vacuum. The crude product of methyl
5,5-dimethyl-4-oxotetrahydrofuran-3-carboxylate (12 g) was used directly for step 2 without further purification.
Step 2: Methyl 5,5-dimethyl-4-oxotetrahydrofuran-3-carboxylate (5.0 g, 29 mmol) was dissolved in 12N HCl (30 mL). The mixture was stirred at 100 °C for 2 hours. Then allowed to cool to rt and pH was adjusted to pH 8 with sat. aqueous NaHCO3 and extracted with MTBE (3x30 mL). The combined organic phases were washed with water (2x30 mL), dried over Na2SO4 and evaporated under vacuum. The crude product of 2,2-dimethyldihydrofuran-3(2H)-one (1.1 g) was used in the next step.
Step 3: 2,2-Dimethyldihydrofuran-3(2H)-one (1.0 g, 8.8 mmol) and 2-methylpropane-2sulfinamide (1.1 g, 8.8 mmol) were dissolved in THF (30 mL). Ti(i-PrO)4 (2.9 g, 10 mmol) was added. The mixture was stirred at 60 °C for 8 hours. The mixture was diluted with ethyl acetate (100 mL) and washed with water (2*50 mL). The organic layer was dried over Na2SO4 and evaporated under vacuum. The residue was purified by silica gel chromatography using a gradient of petroleum ether and ethyl acetate to give N-(2,2-dimethyldihydrofuran-3(2H)ylidene)-2-methylpropane-2-sulfinamide 900 mg (47%).
Step 4: N-(2,2-dimethyldihydrofuran-3(2H)-ylidene)-2-methylpropane-2-sulfinamide (900 mg,
4.1 mmol) was dissolved in THF (30 mL). NaBH4 (310 mg, 8.2 mmol) was added at 0°C. The reaction was then stirred at 20°C for 1 hr. The mixture was quenched with aqueous sat. NH4CI (0.5 mL) and diluted with ethyl acetate (100 mL) and washed with water (30 mL). The organic phase was dried over Na2SO4 and evaporated under vacuum. The crude product (700 mg) was used directly in the next step.
Step 5: N-(2,2-dimethyltetrahydrofuran-3-yl)-2-methylpropane-2-sulfinamide (400 mg, 1.80 mmol) was dissolved in 12 M HCl (80 mL). The mixture was stirred at 50 °C for 2 hrs. The reaction mixture was basified with sat. aqueous NaHCO3 to pH=8 and extracted with DCM (3x10 mL). The combined organic phases were washed with water (2x10 mL), dried over Na2SO4 and evaporated under vacuum. The crude product of 2,2-dimethyltetrahydrofuran-3amine (209 mg) was used directly in the next step.
Step 6: A mixture of 2,2-dimethyltetrahydrofuran-3-amine (209 mg, 1.80 mmol), 4-chloro-7,8dimethoxyquinazoline (500 mg, 1.80 mmol) and DIPEA (470 mg, 3.60 mmol) in DMF (15 mL) was stirred at 100°C for 1 hr. The solvent was removed under vacuum. And the residue was dissolved in DCM (50 mL) and washed with water (3x15 mL). The organic phase was dried over Na2SO4 and evaporated under vacuum. The residue was purified by silica gel chromatography using a gradient of DCM and MeOH to give N-(2,2-dimethyltetrahydrofuran-3-yl)-7,8dimethoxyquinazolin-4-amine 75 mg (13%).
The racemate of N-(2,2-dimethyltetrahydrofuran-3-yl)-7,8-dimethoxyquinazolin-4-amine 75 mg was purified by SFC séparation and numbered according to their order of elution:
Stereoisomer 1 (first eluting by SFC): 30 mg (40%)
LC-MS (m/z) 304.2 (MH+) tR (minutes, method 3) = 1.95.
[a]D 20 -74 (c = 0.10, MeOH).
Stereoisomer 2 (second eluting by SFC) : 30 mg (40%)
LC-MS (m/z) 304.2 (MH+) tR (minutes, method 3) = 1.95. [a]D 20 +67 (c = 0.10, MeOH).
Example 22
7,8-dimethoxy-N-methyl-N-(2-methyltetrahydrofuran-3-yI)quinazolin-4-amine:
Step 1: To a solution of 2-methyltetrahydrofuran-3-amine hydrochloride (mixture of ail four possible stereoisomers) (600 mg, 4.34 mmol) in DMF (10 mL) was added 4-chloro-7,8dimethoxyquinazoline (650 mg, 2.89 mmol) and DIPEA (1.2 g, 9.3 mmol). The reaction was stirred ovemight at 100°C. The reaction mixture was concentrated in vacuo and the residue was diluted with DCM (100 mL), washed with sat. NaHCO3(aq), then brine, dried over Na2SO4 and concentrated in vacuo. The residue was purified by silica gel chromatography (DCM:MeOH=10:1) to afford 700 mg of 7,8-dimethoxy- N-(2-methyltetrahydrofuran-3yl)quinazolin-4-amine (84%).
Step 2: A solution of 7,8-dimethoxy-N-(2-methyltetrahydrofuran-3-yl)quinazolin-4-amine (750 mg, 2.59 mmol) in DMF/THF (2 mL/10mL) was cooled to 0°C. NaH (207 mg, 5.18 mmol, 60% in minerai oil) was added. The mixture was stirred at 0°C for 10 min. Then Mel (736 mg, 5.18 mmol) was added. After the addition, the mixture was allowed to warm to rt and stirred for 1h. The mixture was quenched with sat. NH4CI (aq), extracted with DCM (2x50mL). The combined organic phases were washed with brine, dried over Na2SO4 and concentrated. The residue purified by preparative-HPLC to afford 250 mg of 7,8-dimethoxy-N-methyl-N-(2methyltetrahydrofuran-3-yl)quinazolin-4-amine (32%).
The mixture of ail possible stereoisomers of 7,8-dimethoxy-N-methyl-N-(2methyltetrahydrofuran-3-yl)quinazolin-4-amine 280 mg was purified by SFC séparation twice. The first run separated the two racemic diastereomers. Each of these racemates were then subjected to another SFC-purification and separated into enantiomers.
Stereoisomers 1: 55 mg 1H NMR (CDCI3 400 MHz): δ 8.64 (s, 1H), 7.76 (d, J=9.2 Hz, 1H), 7.13 (d, J=9.2 Hz, 1H), 5.42 (brs, 1H), 4.20-4.14 (m, 1H), 4.07-4.01 (m, 7H), 3.74-3.71 (m, 1H), 3.36 (s, 3H), 2.44-2.39 (m, 1 H), 2.30-2.28 (m, 1 H), 1.28 (d, J=6.4 Hz, 3H).
LC-MS (m/z) 304.1 (MH+) tR (minutes, method 3) = 1.57.
[a]D 20 -47 (c = 0.10, MeOH).
Stereoisomer 2:17 mg 1H NMR (CDCI3 400 MHz): δ 8.67 (s, 1H), 7.71 (d, J=9.2 Hz, 1H), 7.12 (d, J=9.2 Hz, 1H), 4.87 (brs, 1H), 4.15-4.08 (m, 1H), 4.03-3.96 (m, 8H), 3.29 (s, 3H), 2.50-2.43 (m, 1H), 2.10-2.03 (m, 1H), 1.23 (d, J=6.4 Hz, 3H).
LC-MS (m/z) 304.1 (MH+) tR (minutes, method 3) = 1.56.
[a]D 20 +17 (c = 0.10, MeOH).
Stereoisomer 3: 45 mg 1H NMR (CDCI3 400 MHz): δ 8.70 (s, 1H), 7.75 (d, J=9.2 Hz, 1H), 7.17 (d, J=9.2 Hz, 1H), 4.83 (brs, 1H), 4.20-4.14 (m, 1H), 4.08-4.01 (m, 8H), 3.30 (s, 3H), 2.55-2.47 (m, 1H), 2.16-2.07 (m, 1H), 1.28 (d, J=6.0 Hz, 3H).
LC-MS (m/z) 304.1 (MH+) tR (minutes, method 3) = 1.57.
[a]D 20 -17 (c = 0.10, MeOH).
Stereoisomer 4: 25 mg 1H NMR (CDCI3 400 MHz): 5 8.58 (s, 1H), 7.71 (d, J=9.2 Hz, 1H), 7.07 (d, J=9.2 Hz, 1H), 5.34-
5.33 (m, 1H), 4.13-4.09 (m, 1H), 4.01-3.95 (m, 7H), 3.68-3.65 (m, 1H), 3.30 (s, 3H), 2.38-2.34 (m, 1 H), 2.25-2.22 (m, 1 H), 1.23 (d, J=6.4 Hz, 3H).
LC-MS (m/z) 304.1 (MH+) tR (minutes, method 3) = 1.57.
[a]D 20 +56 (c = 0.10, MeOH).
Example 23
7,8-Dimethoxy-N-methyl-N-(3-methyltetrahydrofuran-3-yl)quinazolin-4-amine:
To an ice-cold solution of 7,8-dimethoxy-N-(3-methyltetrahydrofuran-3-yl)quinazolin-4-amine (300 mg, 1.03 mmol) in THF (15mL) was added NaH (60% in minerai oil) (60 mg, 1.5 mmol) at 0 °C and it was then allowed to RT. After stirring at rt for for 30 min. Mel (211 mg, 1.5 mmol) was added. Stirring was continued for 3 hrs. The solution was quenched by addition of sat. NH4CI (aq. 1mL), and subsequently concentrated under vacuum. The residue was diluted with DCM (60mL).The organic layer was washed with water, brine, dried over Na2SO4 and concentrated under vacuum. The residue was purified by flash chromatography silica gel using a gradient of ethyl acetate and petroleum ether to give 7,8-dimethoxy-N-methyl-N-(3-methyltetrahydrofuran-
3-yl)quinazolin-4-amine 260 mg (86%).
The racemate of 7,8-dimethoxy-N-methyl-N-(3-methyltetrahydrofuran-3-yl)quinazolin-4-amine 260 mg was purified by SFC séparation and numbered according to the order of elution:
Stereoisomer 1 (first eluting by SFC): 80 mg
LC-MS (m/z) 304.2 (MH+) tR (minutes, method 3) = 1.81.
[a]D 20 +15 (c = 0.10, MeOH).
Stereoisomer 2 (second eluting by SFC): 74 mg
LC-MS (m/z) 304.2 (MH+) tR (minutes, method 3) = 1.82.
[a]D 20-17 (c = 0.10, MeOH).
Example 24
/V-(3-Ethyltetrahydrofuran-3-yl)-7,8-dimethoxyquinazolin-4-amine:
To a mixture of 4-chloro-7,8-dimethoxyquinazoline (100 mg, 0.445 mmol) and 3ethyltetrahydrofuran-3-amine hydrochloride (68 mg, 0.45 mmol) in isopropanol (1.5 mL) was added DIPEA (144 mg, 1.1 mmol). The mixture was heated under microwave irradiation at 170 °C for 80 min. The reaction mixture was poured into H2O (50 mL) and extracted with ethyl acetate (3x50mL). The combined organic phases were washed with brine, dried over MgSO4 and concentrated in vacuo. The mixture was purified by flash chromatography using a gradient of ethyl acetate and heptane to yield 54 mg /V-(3-ethyltetrahydrofuran-3-yl)-7,8dimethoxyquinazolin-4-amine (48%).
LC-MS (m/z) 304.2 (MH+) tR (minutes, method 2) = 0.39.
Example 25
/V-(2-Cyclopropyltetrahydrofuran-3-yl)-7,8-dimethoxyquinazolin-4-amine:
To a mixture of 4-chloro-7,8-dimethoxyquinazoline (200 mg, 0.890 mmol) and 2cyclopropyltetrahydrofuran-3-amine (170 mg, 1.34 mmol) in isopropanol (10 mL) was added DIPEA (0.311 ml, 1.78 mmol) and the reaction was heated under microwave irradiation at 160 °C for 40 min. After cooling to room température for 4 hours a white precipitate was collected and dried in vacuo at 40°C overnight to yield 80 mg of trans-N-(2-Cyclopropyltetrahydrofuran-3yl)-7,8-dimethoxyquinazolin-4-amine (29%).
LC-MS (m/z) 316.0 (MH+) tR (minutes, method 2) = 0.36.
PDE1 INHIBITION ASSAY
PDE1A, PDE1B and PDE1C assays were performed as follows: the assays was performed in 60 pL samples containing a fixed amount ofthe PDE1 enzyml (sufficientto convert 20-25% of the cyclic nucléotide substrate), a buffer (50 mM HEPES pH 7.6; 10 mM MgCI2; 0.02% Tween20), 0.1 mg/ml BSA, 15 nM tritium labelled cAMP and varying amounts of inhibitors.
Reactions were initiated by addition ofthe cyclic nucléotide substrate, and reactions were allowed to proceed for 1 h at room température before being terminated through mixing with 20 pL (0.2 mg) yttrium silicate SPA beads (PerkinElmer). The beads were allowed to settle for 1 h in the dark before the plates were counted in a Wallac 1450 Microbeta counter. The measured signais were converted to activity relative to an uninhibited control (100%) and IC50 values were calculated using XIFit (model 205, IDBS).
Claims (8)
- Claims1. A compound having the structureCompound (I) whereinR-i is selected from the group consisting of H and Ci-C3 alkyl;R2 is selected from the group consisting of H and CpCs alkyl wherein the C-|-C3 alkyl optionally is substituted with phenyl or C3-C6 cycloalkyl;R3 is selected from the group consisting of H, methyl and ethylR4 is selected from the group consisting of H,, hydroxyl, methoxy and ethoxy and;R5, R6 and R7 are HR8 is selected from the group consisting of H, methyl, ethyl and cyclopropylRg is selected from the group consisting of H, methyl and ethyl and pharmaceutically acceptable acid addition salts of Compound I, racemic mixtures of Compound I, or the corresponding enantiomer and/or optical isomer of Compound I, and polymorphie forms of Compound I as well as tautomeric forms of Compound I.
- 2. The compound according to claim 1, wherein R2 is H.
- 3. The compound according to claim 1, wherein R2 is methyl.
- 4. The compound according to claim 3, wherein R2 is substituted with phenyl or cyclopropyl.
- 5. The compound according to claim 1 selected from the group consisting of7,8-Dimethoxy-N-(tetrahydrofuran-3-yl)quinazolin-4-amine trans-N-(-2-cyclopropyltetrahydrofuran-3-yl)-7,8-dimethoxyquinazolin-4-amine7.8- dimethoxy-N-(-2-methyltetrahydrofuran-3-yl)quinazolin-4-amine (7,8-dimethoxy-N-methyl-N-(tetrahydrofuran-3-yl)quinazolin-4-amine (R) -7,8-dimethoxy-N-methyl-N-(tetrahydrofuran-3-yl)quinazolin-4-amine (S) -7,8-dimethoxy-N-methyl-N-(tetrahydrofuran-3-yl)quinazolin-4-amineN-(2,3-dimethyltetrahydrofuran-3-yl)-7,8-dimethoxyquinazolin-4-amine7.8- dimethoxy-N-(3-methyltetra- hydrofuran-3-yl)quinazolin-4-amine (S)-7,8-dimethoxy-N-(tetrahydrofuran-3-yl)quinazolin-4-amine (S)-N-ethyl-7,8-dimethoxy-N-(tetrahydrofuran-3-yl)quinazolin-4-amine (S)-7,8-dimethoxy-N-propyl-N-(tetrahydrofuran-3-yl)quinazolin-4-amine (S)-N-benzyl-7,8-dimethoxy-N-(tetrahydrofuran-3-yl)quinazolin-4-amine (S)-N-(cyclopropylmethyl)-7,8-dimethoxy-N-(tetrahydrofuran-3-yl)quinazolin-4-amine (R)-7,8-dimethoxy-N-(tetrahydrofuran-3-yl)quinazolin-4-amine (R)-N-ethyl-7,8-dimethoxy-N-(tetrahydrofuran-3-yl)quinazolin-4-amine (R)-7,8-dimethoxy-N-propyl-N-(tetrahydrofuran-3-yl)quinazolin-4-amine (R)-N-(cyclopropylmethyl)-7,8-dimethoxy-N-(tetrahydrofuran-3-yl)quinazolin-4-amine (R)-N-benzyl-7,8-dimethoxy-N-(tetrahydrofuran-3-yl)quinazolin-4-amine trans-7,8-dimethoxy-N-4-methoxytetrahydrofuran-3-yl)quinazolin-4-amine trans-4-((7,8-dimethoxyquinazolin-4-yl)amino)tetrahydrofuran-3-ol cis-4-((7,8-dimethoxyquinazolin-4-y))amino)tetrahydrofuran-3-olN-(2,3-Dimethyltetrahydrofuran-3-yl)-7,8-dimethoxy-N-methylquinazolin-4-amineN-(2,2-dimethyltetrahydrofuran-3-yl)-7,8-dimethoxyquinazolin-4-amine7.8- dimethoxy-N-methyl-N-(2-methyltetrahydrofuran-3-yl)quinazolin-4-amine7.8- dimethoxy-N-methyl-N-(3-methyltetrahydrofuran-3-yl)quinazolin-4-amine /V-(3-Ethyltetrahydrofuran-3-yl)-7,8-dimethoxyquinazolin-4-amine /V-(2-Cyclopropyltetrahydrofuran-3-yl)-7,8-dimethoxyquinazolin-4-amine
- 6. The compound of any of daims 1 to 5, wherein the compound is for use as a médicament.5
- 7. The compound of any of daims 1 to 5, wherein the compound is for use in treatingADHD, schizophrenia or cognitive impairment associated with schizophrenia
- 8. The compound of any of claim 1 to 5 for the manufacture of a médicament for the treatment of ADHD, schizophrenia or cognitive impairment associated with schizophrenia.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA201300707 | 2013-12-19 | ||
DKPA201400249 | 2014-05-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
OA17911A true OA17911A (en) | 2018-02-27 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3204387B1 (en) | Triazolopyrazinones as pde1 inhibitors | |
US10030007B2 (en) | Quinazolin-THF-amines as PDE1 inhibitors | |
US10526319B2 (en) | Halogenated quinazolin-THF-amines as PDE1 inhibitors | |
US9718832B2 (en) | Hexahydrofuropyrroles as PDE1 inhibitors | |
OA17911A (en) | Quinazolin-THF-amines as PDE1 inhibitors. | |
OA18257A (en) | Triazolopyrazinones as PDE 1 inhibitors. | |
OA17878A (en) | Hexahydrofuropyrroles as PDE1 inhibitors. | |
OA18062A (en) | Halogenated quinazolin-THF-amines as PDE1 inhibitors. |